

Inhaltsverzeichnis

GO29781	2
Charakterisierung der Studienpopulationen.....	2
Mortalität.....	17
Gesamtüberleben	17
Morbidität	19
Progressionsfreies Überleben	19
Tumoransprechen	21
EORTC QLQ-C30 Symptomskalen	34
EQ-5D VAS.....	90
Gesundheitsbezogene Lebensqualität	97
EORTC QLQ-C30 Funktionsskalen.....	97
FACT LymS	139
Verträglichkeit	146
Generelle Verträglichkeit	146
Spezifische Verträglichkeit.....	191

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients

ENDPOINT: All patients

MODEL: --

STUDY: GO29781

Key prior cancer treatment data

	B11 Exp 3L FL (RP2D) (N=90)
No. of Prior Lines of Therapy	
n	90
Mean (SD)	3.3 (1.6)
Median	3
Range	2 - 10
No. of Prior Lines of Therapy-distribution	
n	90
2	34 (37.8%)
3	28 (31.1%)
>3	28 (31.1%)
Prior Cancer Therapy Regimen	
Prior auto-Stem Cell Transplant	19 (21.1%)
Prior Anti-CD20 Therapy	90 (100%)
Prior Anti-CD19 Therapy	2 (2.2%)
Prior CAR-T Therapy	3 (3.3%)
Prior Alkylator Therapy	90 (100%)
Prior Anthracyclines	74 (82.2%)
Prior PI3K Inhibitor	17 (18.9%)
Prior BTK Inhibitor	6 (6.7%)
Prior IMiD	13 (14.4%)
R/R to Prior Anti-CD20 Therapy	
n	90
Refractory to Any	71 (78.9%)
Relapse to any (No Refractory)	19 (21.1%)
R/R to Prior Alkylator Therapy	

n	90
Refractory to Any	51 (56.7%)
Relapse to any (No Refractory)	39 (43.3%)
R/R to Last Prior Therapy	
n	90
Refractory	62 (68.9%)
Relapse	27 (30.0%)
Unknown	1 (1.1%)
R/R to Prior CAR-T	
n	3
Refractory to Any	2 (66.7%)
Relapse to any (No Refractory)	1 (33.3%)
R/R to Prior PI3K Inhibitor	
n	17
Refractory to Any	12 (70.6%)
Relapse to any (No Refractory)	5 (29.4%)
Refractory to Any Prior Therapy	
n	90
Refractory	78 (86.7%)
Relapse	12 (13.3%)
Double Refractory to Prior Anti-CD20 and Alkylator Therapies	
n	90
Yes	48 (53.3%)
No	42 (46.7%)
<24 months from start of systemic therapy to PD	
n	90
Yes	47 (52.2%)
No	43 (47.8%)
Time Since Last CD20 (Days)	
n	90
Mean (SD)	595.0 (648.1)
Median	406
Range	26 - 3032

Time Since Last Therapy (Days)	
n	90
Mean (SD)	433.3 (513.9)
Median	203.5
Range	15 - 2717

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/oth_cantrt.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/oth_cantrt_JAN22_SE_B11E.xls

04MAR2022 8:41

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: GO29781
Number of centers/countries/geographical regions with <10, >=10 patients per arm

Category	Center				Country				Geographical region (3)			
	n (4)	% (5)	n of patients randomized (6)	% randomized patients (7)	n (4)	% (5)	n of patients randomized (6)	% randomized patients (7)	n (4)	% (5)	n of patients randomized (6)	% randomized patients (7)
Overall	30	100	90	100	7	100	90	100	3	100	90	100
with <10 patients per arm (1)	29	96.7	80	88.9	4	57.1	20	22.2	0	0	0	0
with >=10 patients per arm (2)	1	3.3	10	11.1	3	42.9	70	77.8	3	100	90	100

(1) "<10 patients category" if at least one treatment arm has <10 patients. (2) ">=10 patients" category if all treatment arms have >=10 patients.
(3) Geographical regions: North America, Western Europe, Asia-Pacific. (4) Number of centers/countries/geographical regions.
(5) % of centers compared to overall number of centers.
(6) Number of patients randomized in the corresponding category (e.g .Number of patients randomized in centers with <10 pts per arm).
(7) % of randomized patients compared to overall number of randomized patients (e.g . % of randomized patients in centers with <10 patients per arm compared to overall number of randomized patients).
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/oth_center.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/oth_center_JAN22_SE_B11E.xls
04MAR2022 8:35

POPULATION: Cohort B11 Expansion FL, Safety-Evaluatable Patients

ENDPOINT: All patients

MODEL: --

STUDY: GO29781

Number of patients who died including primary reason

	B11 Exp 3L FL (RP2D) (N=90)
Total number of deaths	10 (11.1%)
Primary cause of death	
n	10
Adverse event	2 (20.0%)
Progressive disease	7 (70.0%)
Other	1 (10.0%)

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/oth_dd.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/oth_dd_JAN22_SE_B11E.xls
04MAR2022 8:37

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients

ENDPOINT: All patients

MODEL: --

STUDY: GO29781

Key cancer history data

	B11 Exp 3L FL (RP2D) (N=90)
Time from Initial Diagnosis to First Study Treatment (Months)	
n	90
Mean (SD)	94.5 (59.2)
Median	82.2
Range	11 - 292
NHL Subtype at Study Entry	
n	90
FL	90 (100%)
NHL - Study Entry Stage (Ann Arbor Stage)	
n	90
STAGE I	5 (5.6%)
STAGE II	16 (17.8%)
STAGE III	25 (27.8%)
STAGE IV	44 (48.9%)
Time from Last Anti-CD20 to First Mosun Dose Date (Months)	
n	90
Mean (SD)	19.5 (21.3)
Median	13.3
Range	1 - 100
by category:	
< 3 months	23 (25.6%)
>= 3 months	67 (74.4%)
Time from Last Prior Therapy to First Mosun Dose Date (Months)	
n	90

Mean (SD)	14.2 (16.9)
Median	6.7
Range	0 - 89
by category:	
< 3 months	31 (34.4%)
>= 3 months	59 (65.6%)
SPD at Baseline (Initial Treatment)	
n	90
Mean (SD)	3862.6 (3164.3)
Median	3014
Range	234 - 15799
by category:	
< 3000 mm2	45 (50.0%)
>= 3000 mm2	45 (50.0%)
IPI Risk Factors	
n	90
1	4 (4.4%)
2	4 (4.4%)
3	2 (2.2%)
4	1 (1.1%)
Unknown	79 (87.8%)
FL IPI Index 1 Risk Factors	
n	90
0	3 (3.3%)
1	23 (25.6%)
2	24 (26.7%)
3	21 (23.3%)
4	18 (20.0%)
5	1 (1.1%)
Bulky Disease (>6cm)	
Yes	31 (34.4%)
No	59 (65.6%)
Bulky Disease (>7cm)	
Yes	16 (17.8%)

No	74 (82.2%)
Bulky Disease (>10cm)	
Yes	2 (2.2%)
No	88 (97.8%)
EZH2 mutation	
n	51
Mutant	8 (15.7%)
Wild-type	43 (84.3%)

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/oth_dm_canhis.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/oth_dm_canhis_JAN22_SE_B11E.xls

04MAR2022 8:40

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: GO29781
Demographic and Baseline Characteristics

	B11 Exp 3L FL (RP2D) (N=90)
Age (yr)	
n	90
Mean (SD)	60.0 (12.0)
Median	60
Min - Max	29 - 90
Age group (yr)	
n	90
18-65	62 (68.9%)
>65	28 (31.1%)
Sex	
n	90
Male	55 (61.1%)
Female	35 (38.9%)
Ethnicity	
n	90
Hispanic or Latino	7 (7.8%)
Not Hispanic or Latino	77 (85.6%)
Not Stated	5 (5.6%)
Unknown	1 (1.1%)
Race	
n	90
American Indian or Alaska Native	1 (1.1%)
Asian	8 (8.9%)

Black or African American	4 (4.4%)
White	74 (82.2%)
Unknown	3 (3.3%)
Height (cm) at baseline	
n	82
Mean (SD)	169.92 (10.83)
Median	171.45
Min - Max	138.0 - 193.0
ECOG at baseline	
n	90
0	53 (58.9%)
1	37 (41.1%)
BMI (kg/m2) at baseline	
n	82
Mean (SD)	28.24 (5.57)
Median	27.51
Min - Max	17.0 - 45.2

Percentages are based on n for each subsection.

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/oth_dm.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/oth_dm_JAN22_SE_B11E.xls

04MAR2022 8:36

POPULATION: Safety-Evaluable Patients

ENDPOINT: All patients

MODEL: --

STUDY: GO29781

Disposition of Patients

	Screened Patients
	(N=449)
Mosunetuzumab IV monotherapy Group A and B	449 (100%)
Mosunetuzumab IV monotherapy Group B	416 (92.7%)
Mosunetuzumab IV monotherapy Group B11 dose expansion cohort	220 (49.0%)
Received >= 1 dose of Mosunetuzumab	220 (49.0%)
R/R FL received Mosunetuzumab at RP2D	90 (20.0%)
Completed Initial Treatment	54 (12.0%)
Received Retreatment	4 (0.9%)
Disposition at Clinical Cut Off	
ACTIVE ON RE-TREATMENT 1	3 (0.7%)
INITIAL TREATMENT POST-TREATMENT FOLLOW-UP	39 (8.7%)
INITIAL TREATMENT SURVIVAL FOLLOW-UP	33 (7.3%)
RE-TREATMENT 1 SURVIVAL FOLLOW-UP	1 (0.2%)
STUDY DISCONTINUATION/COMPLETION	14 (3.1%)
Discontinued from Initial Treatment	36 (8.0%)

ADVERSE EVENT	4 (0.9%)
PHYSICIAN DECISION	4 (0.9%)
PROGRESSIVE DISEASE	25 (5.6%)
USE OF ANOTHER ANTI-CANCER THERAPY	2 (0.4%)
WITHDRAWAL BY SUBJECT	1 (0.2%)
Discontinued from Post-Treatment Follow-Up (Initial Treatment)	13 (2.9%)
DEATH	1 (0.2%)
PROGRESSIVE DISEASE	10 (2.2%)
USE OF ANOTHER ANTI-CANCER THERAPY	1 (0.2%)
WITHDRAWAL BY SUBJECT	1 (0.2%)
Discontinued from Re-treatment	1 (0.2%)
PROGRESSIVE DISEASE	1 (0.2%)
Discontinued from Study during Initial Treatment	14 (3.1%)
DEATH	1 (0.2%)
DEATH DUE TO ADVERSE EVENT	1 (0.2%)
DEATH DUE TO PROGRESSION OF DISEASE	8 (1.8%)
WITHDRAWAL BY SUBJECT	4 (0.9%)
Discontinued from Study at Any Time	14 (3.1%)
DEATH	1 (0.2%)
DEATH DUE TO ADVERSE EVENT	1 (0.2%)
DEATH DUE TO PROGRESSION OF DISEASE	8 (1.8%)
WITHDRAWAL BY SUBJECT	4 (0.9%)

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/oth_ds.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/oth_ds_JAN22_SE.xls

04MAR2022 8:37

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
 ENDPOINT: All patients
 MODEL: --
 STUDY: GO29781
 Duration of follow-up

	B11 Exp 3L FL (RP2D) (N=90)
Median follow-up time (days)	
n	90
Mean	451.72
Median	479.5
Min - Max	9.0 - 954.0

Median follow-up time is time from patient randomization to study discontinuation date, death date or CCOD, whichever is the earliest.
 Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/oth_fut.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/oth_fut_JAN22_EE_B11E.xls
 11APR2022 14:40

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: GO29781
Duration of follow-up

	B11 Exp 3L FL (RP2D) (N=90)
Median follow-up time (days)	
n	90
Mean	240.74
Median	239
Min - Max	22.0 - 456.0

Median follow-up time is time from first dose to end of 90 day safety follow up period or earliest of CCOD, NALT, study discontinuation or start of a re-treatment.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/oth_fut.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/oth_fut_JAN22_SE_B11E.xls
04MAR2022 8:39


POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients

ENDPOINT: --

MODEL: --

STUDY: GO29781

Time of patient inclusion per center



Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/oth_g_pat_incl.sas.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/oth_g_pat_incl.sas_JAN22_SE_B11E.pdf

04MAR2022 08:39


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: Overall Survival

MODEL: --

STUDY: GO29781

Kaplan-Meier plot of time to first event (months)



Patients at risk												
B11 Exp 3L FL (RP2D)	90	89	86	85	79	69	58	40	29	15	4	NE
Patients censored												
B11 Exp 3L FL (RP2D)	0	0	2	2	5	13	22	40	51	65	76	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_EE_B11E_OS.pdf
12APR2022 9:38


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Overall Survival
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=90)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	90	100.0	10	11.1	80	88.9	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_EE_B11E_OS.xls
12APR2022 9:28

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Progression Free Survival, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)



Patients at risk												
B11 Exp 3L FL (RP2D)	90	74	56	51	43	35	23	19	8	1	NE	NE
Patients censored												
B11 Exp 3L FL (RP2D)	0	2	8	9	12	17	27	31	40	47	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_EE_B11E_PFS_IRF.pdf
12APR2022 9:38


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Progression Free Survival, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=90)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	90	100.0	42	46.7	48	53.3	5.4	3.3	8.9	17.9	10.9	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_EE_B11E_PFS_IRF.xls
12APR2022 9:28

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Duration of Complete Response, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk												
B11 Exp 3L FL (RP2D)	54	51	44	38	28	20	13	10	1	NE	NE	NE
Patients censored												
B11 Exp 3L FL (RP2D)	0	1	3	7	13	19	26	28	37	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_EE_B11E_DOCR_IRF.pdf
12APR2022 9:31

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Duration of Response, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)



Patients at risk												
B11 Exp 3L FL (RP2D)	73	61	51	43	38	28	19	16	2	NE	NE	NE
Patients censored												
B11 Exp 3L FL (RP2D)	0	4	7	9	10	18	27	29	42	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_EE_B11E_DOR_IRF.pdf
12APR2022 9:32

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: Duration of Complete Response, Response Assessed by Independent Oncologists

MODEL: --

STUDY: GO29781

Time to event landmark analysis

	B11 Exp 3L FL (RP2D) (N=90)
Patients included in analysis (%)	54 (60.0%)
Patients with event (%)	16 (29.6%)
Patients without event (%)	38 (70.4%)
Time to event (months)	
Median	NE
95% CI	(18.7, NE)
25% and 75%-ile	9.4 - NE
Range	0.0* - 26.6*
Time point analysis (Unstratified)	
3 Months	
Patients remaining at risk	51
Event free proportion (%)	96.23
95% CI	(91.10, 100.00)
6 Months	
Patients remaining at risk	44
Event free proportion (%)	86.79
95% CI	(77.68, 95.91)
9 Months	

Patients remaining at risk	38
Event free proportion (%)	82.45
95% CI	(72.00, 92.91)
12 Months	
Patients remaining at risk	28
Event free proportion (%)	73.65
95% CI	(61.25, 86.05)
15 Months	
Patients remaining at risk	20
Event free proportion (%)	67.63
95% CI	(53.71, 81.55)
18 Months	
Patients remaining at risk	13
Event free proportion (%)	67.63
95% CI	(53.71, 81.55)
21 Months	
Patients remaining at risk	10
Event free proportion (%)	62.43
95% CI	(46.27, 78.58)
24 Months	
Patients remaining at risk	1
Event free proportion (%)	62.43
95% CI	(46.27, 78.58)

* Censored values.

Summaries of time to event (median, percentiles) are based on Kaplan-Meier estimates.

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_lma.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_lma_JAN22_EE_B11E_DOCR_IRF.xls

12APR2022 13:35

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Objective Response Rate, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Dichotomous analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	73	81.1	71.8	87.9

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_resp.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_resp_JAN22_EE_B11E_OR_IRF.xls
12APR2022 9:14

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Objective Response Rate, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Dichotomous analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	71	78.9	69.4	86.0

95% CI based on Wilson Scores.
Clinical cut-off: 15MAR2021

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_resp.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_CSRPrimary_GrpAB_May2021/prod/output/eff_resp_MAR21_EE_B11E_OR_IRF.xls
26JAN2022 8:28

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Best Overall Response, Response Assessed by Investigator
MODEL: --
STUDY: GO29781
Dichotomous analysis (efficacy)

			B11 Exp 3L FL (RP2D) (N=90)					
			Patients		Patients with Event			
Name	Parameter	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	CR	n/a	90	100.0	54	60.0	49.7	69.5
	PR	n/a	90	100.0	16	17.8	11.2	26.9
	SD	n/a	90	100.0	8	8.9	4.6	16.6
	PD	n/a	90	100.0	10	11.1	6.1	19.3
	NE	n/a	90	100.0	1	1.1	0.2	6.0
	Missing or No Data	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_resp_new.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_resp_new_JAN22_EE_B11E_BOR_INV.xls
12APR2022 9:18

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Best Overall Response, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Dichotomous analysis (efficacy)

			B11 Exp 3L FL (RP2D) (N=90)					
			Patients		Patients with Event			
Name	Parameter	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	CR	n/a	90	100.0	54	60.0	49.7	69.5
	PR	n/a	90	100.0	19	21.1	14.0	30.6
	SD	n/a	90	100.0	7	7.8	3.8	15.2
	PD	n/a	90	100.0	9	10.0	5.4	17.9
	NE	n/a	90	100.0	0	0.0	0.0	4.1
	Missing or No Data	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_resp_new.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_resp_new_JAN22_EE_B11E_BOR_IRF.xls
12APR2022 9:17

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Best Overall Response, Response Assessed by Investigator
MODEL: --
STUDY: GO29781
Dichotomous analysis (efficacy)

			B11 Exp 3L FL (RP2D) (N=90)					
			Patients		Patients with Event			
Name	Parameter	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	CR	n/a	90	100.0	51	56.7	46.4	66.4
	PR	n/a	90	100.0	19	21.1	14.0	30.6
	SD	n/a	90	100.0	8	8.9	4.6	16.6
	PD	n/a	90	100.0	10	11.1	6.1	19.3
	NE	n/a	90	100.0	1	1.1	0.2	6.0
	Missing or No Data	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 15MAR2021

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_resp_new.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_CSRPrimary_GrpAB_May2021/prod/output/eff_resp_new_MAR21_EE_B11E_BOR_INV.xls
26JAN2022 8:30

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Best Overall Response, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Dichotomous analysis (efficacy)

			B11 Exp 3L FL (RP2D) (N=90)					
			Patients		Patients with Event			
Name	Parameter	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	CR	n/a	90	100.0	52	57.8	47.5	67.5
	PR	n/a	90	100.0	19	21.1	14.0	30.6
	SD	n/a	90	100.0	8	8.9	4.6	16.6
	PD	n/a	90	100.0	9	10.0	5.4	17.9
	NE	n/a	90	100.0	0	0.0	0.0	4.1
	Missing or No Data	n/a	90	100.0	2	2.2	0.6	7.7

95% CI based on Wilson Scores.
Clinical cut-off: 15MAR2021

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_resp_new.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_CSRPrimary_GrpAB_May2021/prod/output/eff_resp_new_MAR21_EE_B11E_BOR_IRF.xls
26JAN2022 8:29

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Duration of Complete Response, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=90)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	54	60.0	16	29.6	38	70.4	9.4	7.2	NE	NE	18.7	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_EE_B11E_DOCR_IRF.xls
12APR2022 9:22

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: Duration of Response, Response Assessed by Independent Oncologists
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=90)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	73	81.1	29	39.7	44	60.3	7.2	4.1	9.7	22.8	13.7	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_EE_B11E_DOR_IRF.xls
12APR2022 9:22


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss

MODEL: --

STUDY: GO29781

Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30AP.pdf
11APR2022 14:22


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Constipation

MODEL: --

STUDY: GO29781

Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30CO.pdf
11APR2022 14:19


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea

MODEL: --

STUDY: GO29781

Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30DI.pdf
11APR2022 14:18


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea

MODEL: --

STUDY: GO29781


Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30DY.pdf
11APR2022 14:17

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue
MODEL: --
STUDY: GO29781
Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
 Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30FA.pdf
 11APR2022 14:16


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting

MODEL: --

STUDY: GO29781

Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30NV.pdf
11APR2022 14:17


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Pain

MODEL: --

STUDY: GO29781

Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30PA.pdf
11APR2022 14:24


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Insomnia

MODEL: --

STUDY: GO29781


Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30SL.pdf
11APR2022 14:15

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	81	78	75	69	64	27	18	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	55	64	66	69	70	70	78	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_APPRO_B11E_M10C30AP.pdf
11APR2022 15:55

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	81	78	75	69	64	27	18	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	55	64	66	69	70	70	78	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_APPRO_B11E_M15C30AP.pdf
 11APR2022 16:13

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Constipation (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	81	80	77	74	68	63	27	18	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	54	63	65	68	69	69	77	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_COPRO_B11E_M10C30CO.pdf
 11APR2022 15:54

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Constipation (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	81	80	77	74	68	63	27	18	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	54	63	65	68	69	69	77	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_COPRO_B11E_M15C30CO.pdf
 11APR2022 16:11

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	81	80	77	74	68	63	26	17	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	55	64	65	68	69	69	77	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_DIPRO_B11E_M10C30DI.pdf
 11APR2022 15:50

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	81	80	77	74	68	63	26	17	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	55	64	65	68	69	69	77	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_DIPRO_B11E_M15C30DI.pdf
 11APR2022 16:09

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	80	79	76	73	67	62	25	18	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	55	62	64	67	68	68	76	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_DYPRO_B11E_M10C30DY.pdf
 11APR2022 15:49

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	80	79	76	73	67	62	25	18	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	55	62	64	67	68	68	76	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_DYPRO_B11E_M15C30DY.pdf
 11APR2022 16:08

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	38	36	33	26	21	10	7	6	4	3	3	1	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	1	2	6	9	19	20	20	22	22	22	24	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_FAPRO_B11E_M10C30FA.pdf
11APR2022 15:47

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	55	51	45	40	33	15	11	11	9	8	7	3	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	2	3	6	10	15	33	36	36	38	38	39	43	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_FAPRO_B11E_M15C30FA.pdf
11APR2022 16:07

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting (MID 10, worsening)
 MODEL: --
 STUDY: GO29781
 Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	69	67	63	59	52	22	14	12	9	8	8	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	2	4	8	12	39	46	48	51	52	52	57	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
 Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_NVPRO_B11E_M10C30NV.pdf
 11APR2022 15:48

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	69	67	63	59	52	22	14	12	9	8	8	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	2	4	8	12	39	46	48	51	52	52	57	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_NVPRO_B11E_M15C30NV.pdf
11APR2022 16:07

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Pain (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	55	52	46	39	35	15	9	9	7	6	6	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	0	1	2	5	9	28	32	32	33	34	34	38	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_PAPRO_B11E_M10C30PA.pdf
11APR2022 15:57

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Pain (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)



Patients at risk															
B11 Exp 3L FL (RP2D)	82	55	52	46	39	35	15	9	9	7	6	6	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	0	1	2	5	9	28	32	32	33	34	34	38	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_PAPRO_B11E_M15C30PA.pdf
11APR2022 16:14


POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Insomnia (MID 10, worsening)

MODEL: --

STUDY: GO29781

Kaplan-Meier plot of time to first event (months)



Patients at risk															
B11 Exp 3L FL (RP2D)	82	81	78	75	69	64	27	18	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	55	64	66	69	70	70	78	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_SLPRO_B11E_M10C30SL.pdf
11APR2022 15:47


POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Insomnia (MID 15, worsening)

MODEL: --

STUDY: GO29781

Kaplan-Meier plot of time to first event (months)



Patients at risk															
B11 Exp 3L FL (RP2D)	82	81	78	75	69	64	27	18	16	13	12	12	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	13	18	55	64	66	69	70	70	78	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_SLPRO_B11E_M15C30SL.pdf
11APR2022 16:04

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	85	94.4	1.22	0.56
CYCLE 2 DAY 1	n/a	87	96.7	82	94.3	1.48	0.69
CYCLE 4 DAY 1	n/a	81	90.0	78	96.3	1.13	0.34
CYCLE 6 DAY 1	n/a	71	78.9	68	95.8	1.18	0.46
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	1.24	0.59
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	1.23	0.44
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	1.36	0.81
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	1.55	1.04
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	1.13	0.35
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	1.36	0.66

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Constipation
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	84	93.3	1.37	0.72
CYCLE 2 DAY 1	n/a	87	96.7	82	94.3	1.50	0.72
CYCLE 4 DAY 1	n/a	81	90.0	78	96.3	1.38	0.65
CYCLE 6 DAY 1	n/a	71	78.9	68	95.8	1.22	0.48
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	1.17	0.46
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	1.31	0.48
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	1.27	0.65
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	1.09	0.30
CYCLE 16 DAY 1	n/a	11	12.2	7	63.6	1.00	0.00
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	1.26	0.56

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	84	93.3	1.25	0.53
CYCLE 2 DAY 1	n/a	87	96.7	81	93.1	1.23	0.45
CYCLE 4 DAY 1	n/a	81	90.0	75	92.6	1.15	0.36
CYCLE 6 DAY 1	n/a	71	78.9	67	94.4	1.18	0.46
CYCLE 8 DAY 1	n/a	69	76.7	60	87.0	1.15	0.40
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	1.38	0.51
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	1.00	0.00
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	1.18	0.40
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	1.13	0.35
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	1.34	0.63

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	83	92.2	1.66	0.93
CYCLE 2 DAY 1	n/a	87	96.7	82	94.3	1.49	0.67
CYCLE 4 DAY 1	n/a	81	90.0	78	96.3	1.40	0.61
CYCLE 6 DAY 1	n/a	71	78.9	68	95.8	1.31	0.53
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	1.40	0.61
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	1.62	0.87
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	1.36	0.67
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	1.36	0.81
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	1.25	0.46
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	1.44	0.77

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluatable Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	85	94.4	30.59	24.62
CYCLE 2 DAY 1	n/a	87	96.7	82	94.3	37.20	23.50
CYCLE 4 DAY 1	n/a	81	90.0	78	96.3	26.00	20.66
CYCLE 6 DAY 1	n/a	71	78.9	68	95.8	23.37	20.87
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	25.22	22.24
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	29.06	18.45
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	25.25	21.14
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	35.35	27.59
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	19.44	22.02
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	29.52	26.54

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	85	94.4	3.33	8.83
CYCLE 2 DAY 1	n/a	87	96.7	82	94.3	6.10	11.86
CYCLE 4 DAY 1	n/a	81	90.0	78	96.3	2.35	11.93
CYCLE 6 DAY 1	n/a	71	78.9	68	95.8	2.21	8.59
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	3.17	8.91
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	8.97	16.12
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	6.06	15.41
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	0.00	0.00
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	2.08	5.89
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	4.76	9.89

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Pain
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	85	94.4	16.86	23.50
CYCLE 2 DAY 1	n/a	87	96.7	82	94.3	23.37	27.57
CYCLE 4 DAY 1	n/a	81	90.0	78	96.3	11.75	18.24
CYCLE 6 DAY 1	n/a	71	78.9	68	95.8	12.50	22.19
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	11.11	16.93
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	21.79	19.70
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	24.24	23.99
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	22.73	25.03
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	18.75	31.42
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	15.00	23.08

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Insomnia
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	85	94.4	1.89	1.01
CYCLE 2 DAY 1	n/a	87	96.7	81	93.1	2.04	0.95
CYCLE 4 DAY 1	n/a	81	90.0	78	96.3	1.81	0.82
CYCLE 6 DAY 1	n/a	71	78.9	67	94.4	1.72	0.79
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	1.86	0.93
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	1.92	0.76
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	1.82	0.87
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	1.73	0.79
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	1.50	0.76
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	69	78.4	1.72	0.89

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	82	82	0	NE	NE
CYCLE 2 DAY 1	All	n/a	82	80	80	0.250	0.076
CYCLE 4 DAY 1	All	n/a	76	75	75	-0.067	0.038
CYCLE 6 DAY 1	All	n/a	66	64	64	0.016	0.057
CYCLE 8 DAY 1	All	n/a	64	59	59	0.085	0.077
CYCLE 10 DAY 1	All	n/a	15	13	13	0.000	0.087
CYCLE 12 DAY 1	All	n/a	13	11	11	0.091	0.089
CYCLE 14 DAY 1	All	n/a	12	11	11	0.273	0.285
CYCLE 16 DAY 1	All	n/a	11	8	8	NE	NE
INITIAL TREATMENT COMP OR DISC	All	n/a	80	68	68	0.147	0.081

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_APPRO_B11E_C30AP.xls
 11APR2022 19:50

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Constipation
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	81	81	0	NE	NE
CYCLE 2 DAY 1	All	n/a	81	79	79	0.139	0.077
CYCLE 4 DAY 1	All	n/a	75	74	74	0.041	0.068
CYCLE 6 DAY 1	All	n/a	65	63	63	-0.111	0.053
CYCLE 8 DAY 1	All	n/a	63	58	58	-0.086	0.057
CYCLE 10 DAY 1	All	n/a	15	13	13	0.077	0.130
CYCLE 12 DAY 1	All	n/a	13	11	11	0.182	0.204
CYCLE 14 DAY 1	All	n/a	12	11	11	-0.091	0.095
CYCLE 16 DAY 1	All	n/a	11	7	7	NE	NE
INITIAL TREATMENT COMP OR DISC	All	n/a	79	67	67	-0.104	0.063

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_COPRO_B11E_C30CO.xls
 11APR2022 19:49

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	81	81	0	NE	NE
CYCLE 2 DAY 1	All	n/a	81	78	78	0.000	0.050
CYCLE 4 DAY 1	All	n/a	75	72	72	-0.125	0.041
CYCLE 6 DAY 1	All	n/a	65	62	62	-0.113	0.049
CYCLE 8 DAY 1	All	n/a	63	55	55	-0.091	0.052
CYCLE 10 DAY 1	All	n/a	14	13	13	0.231	0.124
CYCLE 12 DAY 1	All	n/a	13	11	11	NE	NE
CYCLE 14 DAY 1	All	n/a	12	11	11	NE	NE
CYCLE 16 DAY 1	All	n/a	11	8	8	NE	NE
INITIAL TREATMENT COMP OR DISC	All	n/a	79	67	67	0.060	0.076

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_DIPRO_B11E_C30DI.xls
 11APR2022 19:49

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	80	80	0	NE	NE
CYCLE 2 DAY 1	All	n/a	80	78	78	-0.154	0.067
CYCLE 4 DAY 1	All	n/a	74	73	73	-0.233	0.071
CYCLE 6 DAY 1	All	n/a	64	62	62	-0.258	0.068
CYCLE 8 DAY 1	All	n/a	62	57	57	-0.140	0.079
CYCLE 10 DAY 1	All	n/a	15	13	13	0.077	0.179
CYCLE 12 DAY 1	All	n/a	13	11	11	-0.091	0.156
CYCLE 14 DAY 1	All	n/a	12	11	11	-0.273	0.142
CYCLE 16 DAY 1	All	n/a	11	8	8	-0.125	0.064
INITIAL TREATMENT COMP OR DISC	All	n/a	78	66	66	-0.212	0.094

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_DYPRO_B11E_C30DY.xls
 11APR2022 19:49

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Fatigue
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	82	82	0	NE	NE
CYCLE 2 DAY 1	All	n/a	82	80	80	8.542	2.378
CYCLE 4 DAY 1	All	n/a	76	75	75	-1.852	2.208
CYCLE 6 DAY 1	All	n/a	66	64	64	-1.389	2.341
CYCLE 8 DAY 1	All	n/a	64	59	59	1.695	2.618
CYCLE 10 DAY 1	All	n/a	15	13	13	-1.709	3.775
CYCLE 12 DAY 1	All	n/a	13	11	11	-1.010	5.041
CYCLE 14 DAY 1	All	n/a	12	11	11	3.030	5.706
CYCLE 16 DAY 1	All	n/a	11	8	8	-5.556	5.910
INITIAL TREATMENT COMP OR DISC	All	n/a	80	68	68	-1.144	3.005

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_FAPRO_B11E_C30FA.xls
 11APR2022 19:48

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	82	82	0	NE	NE
CYCLE 2 DAY 1	All	n/a	82	80	80	2.708	1.248
CYCLE 4 DAY 1	All	n/a	76	75	75	-0.667	1.414
CYCLE 6 DAY 1	All	n/a	66	64	64	-0.781	0.998
CYCLE 8 DAY 1	All	n/a	64	59	59	-0.565	1.060
CYCLE 10 DAY 1	All	n/a	15	13	13	5.128	2.957
CYCLE 12 DAY 1	All	n/a	13	11	11	1.515	3.705
CYCLE 14 DAY 1	All	n/a	12	11	11	NE	NE
CYCLE 16 DAY 1	All	n/a	11	8	8	0.000	2.227
INITIAL TREATMENT COMP OR DISC	All	n/a	80	68	68	0.735	1.187

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_NVPRO_B11E_C30NV.xls
 11APR2022 19:48

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Pain
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	82	82	0	NE	NE
CYCLE 2 DAY 1	All	n/a	82	80	80	7.500	2.995
CYCLE 4 DAY 1	All	n/a	76	75	75	-3.778	1.966
CYCLE 6 DAY 1	All	n/a	66	64	64	-0.260	2.733
CYCLE 8 DAY 1	All	n/a	64	59	59	-1.130	1.977
CYCLE 10 DAY 1	All	n/a	15	13	13	-1.282	3.494
CYCLE 12 DAY 1	All	n/a	13	11	11	-1.515	4.378
CYCLE 14 DAY 1	All	n/a	12	11	11	-3.030	4.693
CYCLE 16 DAY 1	All	n/a	11	8	8	-4.167	2.944
INITIAL TREATMENT COMP OR DISC	All	n/a	80	68	68	-1.716	2.612

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_PAPRO_B11E_C30PA.xls
 11APR2022 19:51

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Insomnia
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	82	82	0	NE	NE
CYCLE 2 DAY 1	All	n/a	82	79	79	0.203	0.104
CYCLE 4 DAY 1	All	n/a	76	75	75	-0.027	0.080
CYCLE 6 DAY 1	All	n/a	66	63	63	-0.016	0.085
CYCLE 8 DAY 1	All	n/a	64	59	59	0.169	0.117
CYCLE 10 DAY 1	All	n/a	15	13	13	0.385	0.191
CYCLE 12 DAY 1	All	n/a	13	11	11	0.182	0.246
CYCLE 14 DAY 1	All	n/a	12	11	11	0.091	0.159
CYCLE 16 DAY 1	All	n/a	11	8	8	0.000	0.191
INITIAL TREATMENT COMP OR DISC	All	n/a	80	67	67	-0.134	0.097

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_SLPRO_B11E_C30SL.xls
 11APR2022 19:47

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	0	0.0	82	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_APPRO_B11E_M10C30AP.xls
11APR2022 15:23

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	0	0.0	82	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_APPRO_B11E_M15C30AP.xls
11APR2022 15:39

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Constipation (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=81)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	81	100.0	0	0.0	81	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_COPRO_B11E_M10C30CO.xls
11APR2022 15:22

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Constipation (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=81)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	81	100.0	0	0.0	81	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_COPRO_B11E_M15C30CO.xls
11APR2022 15:37

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=81)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	81	100.0	0	0.0	81	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_DIPRO_B11E_M10C30DI.xls
11APR2022 15:19

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=81)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	81	100.0	0	0.0	81	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_DIPRO_B11E_M15C30DI.xls
11APR2022 15:36

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=80)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	80	100.0	0	0.0	80	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_DYPRO_B11E_M10C30DY.xls
11APR2022 15:18

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=80)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	80	100.0	0	0.0	80	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_DYPRO_B11E_M15C30DY.xls
11APR2022 15:35

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	57	69.5	25	30.5	0.7	0.7	0.8	1.0	0.8	3.5

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_FAPRO_B11E_M10C30FA.xls
11APR2022 15:15

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	36	43.9	46	56.1	0.8	0.7	2.1	9.1	3.3	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_FAPRO_B11E_M15C30FA.xls
11APR2022 15:34

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	23	28.0	59	72.0	5.6	2.1	NE	NE	11.1	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_NVPRO_B11E_M10C30NV.xls
11APR2022 15:17

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	23	28.0	59	72.0	5.6	2.1	NE	NE	11.1	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_NVPRO_B11E_M15C30NV.xls
11APR2022 15:35

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Pain (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	42	51.2	40	48.8	0.7	0.7	1.9	6.4	2.2	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_PAPRO_B11E_M10C30PA.xls
11APR2022 15:25

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Pain (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	42	51.2	40	48.8	0.7	0.7	1.9	6.4	2.2	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_PAPRO_B11E_M15C30PA.xls
11APR2022 15:40

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Insomnia (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	0	0.0	82	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_SLPRO_B11E_M10C30SL.xls
11APR2022 15:13

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Insomnia (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	0	0.0	82	100.0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_SLPRO_B11E_M15C30SL.xls
11APR2022 15:33


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EQ5D VAS Score

MODEL: --

STUDY: GO29781

Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_EQVAS.pdf
11APR2022 14:28


POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients

ENDPOINT: EQ-5D-5L VAS (MID 10, worsening)

MODEL: --

STUDY: GO29781

Kaplan-Meier plot of time to first event (months)



Patients at risk															
B11 Exp 3L FL (RP2D)	78	62	58	41	36	31	10	5	5	4	4	4	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	0	2	4	7	9	29	34	34	35	35	35	37	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_EQPRO_B11E_M10VAS.pdf
11APR2022 16:01


POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients

ENDPOINT: EQ-5D-5L VAS (MID 15, worsening)

MODEL: --

STUDY: GO29781

Kaplan-Meier plot of time to first event (months)



Patients at risk															
B11 Exp 3L FL (RP2D)	78	68	65	50	43	39	15	7	6	5	5	5	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	4	6	9	13	16	39	47	48	49	49	49	51	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_EQPRO_B11E_M15VAS.pdf
11APR2022 16:23

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EQ5D VAS Score
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	81	90.0	73.41	20.09
CYCLE 2 DAY 1	n/a	87	96.7	78	89.7	74.71	19.21
CYCLE 4 DAY 1	n/a	81	90.0	74	91.4	78.49	16.47
CYCLE 6 DAY 1	n/a	71	78.9	65	91.5	80.92	15.01
CYCLE 8 DAY 1	n/a	69	76.7	61	88.4	79.21	17.58
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	72.69	19.75
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	76.36	17.48
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	73.73	19.20
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	83.00	14.01
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	68	77.3	78.34	16.74

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EQ5D VAS Score
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	78	78	0	NE	NE
CYCLE 2 DAY 1	All	n/a	78	72	72	-0.167	1.260
CYCLE 4 DAY 1	All	n/a	72	68	68	5.309	1.469
CYCLE 6 DAY 1	All	n/a	63	58	58	4.310	1.744
CYCLE 8 DAY 1	All	n/a	61	55	55	3.273	1.771
CYCLE 10 DAY 1	All	n/a	14	13	13	3.462	3.606
CYCLE 12 DAY 1	All	n/a	13	11	11	6.364	2.855
CYCLE 14 DAY 1	All	n/a	12	11	11	5.091	4.625
CYCLE 16 DAY 1	All	n/a	11	8	8	13.000	3.850
INITIAL TREATMENT COMP OR DISC	All	n/a	76	65	65	4.169	1.970

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_EQPRO_B11E_EQVAS.xls
 11APR2022 19:53

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EQ-5D-5L VAS (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=78)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100.0	39	50.0	39	50.0	2.1	0.7	2.1	4.9	2.3	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_EQPRO_B11E_M10VAS.xls
11APR2022 15:31

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EQ-5D-5L VAS (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=78)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100.0	25	32.1	53	67.9	2.8	2.1	NE	NE	11.3	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_EQPRO_B11E_M15VAS.xls
11APR2022 15:45


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning

MODEL: --

STUDY: GO29781

Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30CF.pdf
11APR2022 14:26


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning

MODEL: --

STUDY: GO29781


Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30EF.pdf
11APR2022 14:26

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning
MODEL: --
STUDY: GO29781
Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30PF.pdf
11APR2022 14:23


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: EORTC QLQ-C30: Scale Global Health Status

MODEL: --

STUDY: GO29781


Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30QL.pdf
11APR2022 14:21


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning
MODEL: --
STUDY: GO29781
Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30RF.pdf
11APR2022 14:25


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning
MODEL: --
STUDY: GO29781
Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_C30SF.pdf
11APR2022 14:27

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	80	53	51	41	37	33	13	6	6	4	4	4	1	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	2	3	5	9	25	31	31	33	33	33	36	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_CFPRO_B11E_M10C30CF.pdf
11APR2022 16:00

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	80	53	51	41	37	33	13	6	6	4	4	4	1	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	2	3	5	9	25	31	31	33	33	33	36	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_CFPRO_B11E_M15C30CF.pdf
11APR2022 16:21

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	80	67	64	57	49	44	19	13	13	11	10	10	3	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	12	16	38	42	42	44	45	45	50	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_EFPRO_B11E_M10C30EF.pdf
11APR2022 15:59

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	80	67	64	57	49	44	19	13	13	11	10	10	3	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	7	12	16	38	42	42	44	45	45	50	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_EFPRO_B11E_M15C30EF.pdf
11APR2022 16:18

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	69	67	54	46	42	18	10	9	8	7	7	3	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	0	2	4	8	11	31	38	38	39	39	39	43	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_PFPRO_B11E_M10C30PF.pdf
11APR2022 15:56

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	77	74	65	57	52	22	15	13	11	10	10	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	4	6	10	15	41	48	49	50	51	51	57	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_PFPRO_B11E_M15C30PF.pdf
11APR2022 16:14

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Global Health Status (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	68	48	47	39	30	26	10	9	9	8	8	8	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	2	4	8	11	27	28	28	29	29	29	35	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_QLPRO_B11E_M10C30QL.pdf
11APR2022 15:54

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Global Health Status (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	68	48	47	39	30	26	10	9	9	8	8	8	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	2	4	8	11	27	28	28	29	29	29	35	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_QLPRO_B11E_M15C30QL.pdf
11APR2022 16:12

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	48	46	40	31	26	9	8	8	6	5	5	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	1	3	7	10	25	26	26	28	29	29	32	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_RFPRO_B11E_M10C30RF.pdf
11APR2022 15:58

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	82	48	46	40	31	26	9	8	8	6	5	5	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	1	3	7	10	25	26	26	28	29	29	32	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_g_tte_JAN22_RFPRO_B11E_M15C30RF.pdf
11APR2022 16:16

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	80	48	46	40	37	35	14	8	8	6	5	5	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	0	1	2	4	6	26	31	31	33	34	34	37	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_SFPRO_B11E_M10C30SF.pdf
11APR2022 16:00

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)



Patients at risk															
B11 Exp 3L FL (RP2D)	80	48	46	40	37	35	14	8	8	6	5	5	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	0	1	2	4	6	26	31	31	33	34	34	37	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_SFPRO_B11E_M15C30SF.pdf
11APR2022 16:22

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	83	92.2	86.55	15.93
CYCLE 2 DAY 1	n/a	87	96.7	81	93.1	84.98	16.79
CYCLE 4 DAY 1	n/a	81	90.0	75	92.6	85.56	16.52
CYCLE 6 DAY 1	n/a	71	78.9	67	94.4	85.07	19.05
CYCLE 8 DAY 1	n/a	69	76.7	60	87.0	81.94	20.42
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	76.92	25.94
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	78.79	19.85
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	83.33	23.57
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	81.25	24.30
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	84.52	19.52

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	83	92.2	79.82	19.13
CYCLE 2 DAY 1	n/a	87	96.7	81	93.1	82.72	18.48
CYCLE 4 DAY 1	n/a	81	90.0	75	92.6	84.96	17.26
CYCLE 6 DAY 1	n/a	71	78.9	67	94.4	84.95	18.02
CYCLE 8 DAY 1	n/a	69	76.7	60	87.0	85.97	17.79
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	77.56	20.80
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	86.36	11.94
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	75.00	21.41
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	86.46	13.32
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	81.67	22.14

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	85	94.4	83.78	20.41
CYCLE 2 DAY 1	n/a	87	96.7	82	94.3	83.37	17.01
CYCLE 4 DAY 1	n/a	81	90.0	77	95.1	86.41	15.16
CYCLE 6 DAY 1	n/a	71	78.9	68	95.8	87.25	13.17
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	86.53	16.56
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	80.51	25.31
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	81.82	20.24
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	74.55	24.00
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	86.67	17.46
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	83.52	20.98

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Global Health Status
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	72	80.0	67.25	27.28
CYCLE 2 DAY 1	n/a	87	96.7	64	73.6	58.72	24.78
CYCLE 4 DAY 1	n/a	81	90.0	57	70.4	72.51	22.82
CYCLE 6 DAY 1	n/a	71	78.9	54	76.1	75.00	22.08
CYCLE 8 DAY 1	n/a	69	76.7	50	72.5	74.67	23.08
CYCLE 10 DAY 1	n/a	15	16.7	9	60.0	68.52	26.28
CYCLE 12 DAY 1	n/a	13	14.4	9	69.2	73.15	26.93
CYCLE 14 DAY 1	n/a	12	13.3	8	66.7	71.87	28.50
CYCLE 16 DAY 1	n/a	11	12.2	6	54.5	76.39	21.35
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	57	64.8	71.20	26.31

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	85	94.4	79.22	29.42
CYCLE 2 DAY 1	n/a	87	96.7	82	94.3	70.73	28.40
CYCLE 4 DAY 1	n/a	81	90.0	78	96.3	82.48	21.97
CYCLE 6 DAY 1	n/a	71	78.9	68	95.8	86.03	18.12
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	82.01	24.00
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	74.36	27.74
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	80.30	26.69
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	69.70	34.01
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	87.50	24.80
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	79.76	25.04

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluatable Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	83	92.2	77.71	27.08
CYCLE 2 DAY 1	n/a	87	96.7	81	93.1	72.02	26.06
CYCLE 4 DAY 1	n/a	81	90.0	75	92.6	84.22	20.85
CYCLE 6 DAY 1	n/a	71	78.9	67	94.4	86.32	21.70
CYCLE 8 DAY 1	n/a	69	76.7	60	87.0	82.50	27.00
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	79.49	28.18
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	83.33	22.36
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	80.30	27.71
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	85.42	27.37
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	80.00	27.16

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	80	80	0	NE	NE
CYCLE 2 DAY 1	All	n/a	80	77	77	-1.948	1.781
CYCLE 4 DAY 1	All	n/a	74	71	71	-0.704	1.787
CYCLE 6 DAY 1	All	n/a	64	61	61	-2.732	2.081
CYCLE 8 DAY 1	All	n/a	62	55	55	-4.242	2.373
CYCLE 10 DAY 1	All	n/a	14	13	13	0.000	7.422
CYCLE 12 DAY 1	All	n/a	13	11	11	4.545	4.723
CYCLE 14 DAY 1	All	n/a	12	11	11	9.091	6.052
CYCLE 16 DAY 1	All	n/a	11	8	8	2.083	4.049
INITIAL TREATMENT COMP OR DISC	All	n/a	78	66	66	-1.515	2.010

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_CFPRO_B11E_C30CF.xls
 11APR2022 19:52

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	80	80	0	NE	NE
CYCLE 2 DAY 1	All	n/a	80	77	77	1.515	1.893
CYCLE 4 DAY 1	All	n/a	74	71	71	5.477	1.699
CYCLE 6 DAY 1	All	n/a	64	61	61	3.962	2.104
CYCLE 8 DAY 1	All	n/a	62	55	55	4.242	1.848
CYCLE 10 DAY 1	All	n/a	14	13	13	4.487	4.736
CYCLE 12 DAY 1	All	n/a	13	11	11	12.879	3.356
CYCLE 14 DAY 1	All	n/a	12	11	11	5.303	5.277
CYCLE 16 DAY 1	All	n/a	11	8	8	14.583	3.276
INITIAL TREATMENT COMP OR DISC	All	n/a	78	66	66	1.641	2.380

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_EFPRO_B11E_C30EF.xls
 11APR2022 19:52

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	82	82	0	NE	NE
CYCLE 2 DAY 1	All	n/a	82	80	80	-1.062	1.209
CYCLE 4 DAY 1	All	n/a	76	74	74	1.081	1.554
CYCLE 6 DAY 1	All	n/a	66	64	64	-0.521	1.418
CYCLE 8 DAY 1	All	n/a	64	59	59	-1.328	1.527
CYCLE 10 DAY 1	All	n/a	15	13	13	0.513	2.887
CYCLE 12 DAY 1	All	n/a	13	11	11	-1.818	3.708
CYCLE 14 DAY 1	All	n/a	12	11	11	-2.424	2.465
CYCLE 16 DAY 1	All	n/a	11	8	8	0.833	2.356
INITIAL TREATMENT COMP OR DISC	All	n/a	80	68	68	-0.270	2.116

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrms.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrms_JAN22_FFPRO_B11E_C30PF.xls
 11APR2022 19:50

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Global Health Status
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	68	68	0	NE	NE
CYCLE 2 DAY 1	All	n/a	68	55	55	-8.182	2.899
CYCLE 4 DAY 1	All	n/a	63	48	48	1.910	2.879
CYCLE 6 DAY 1	All	n/a	54	42	42	-0.198	3.388
CYCLE 8 DAY 1	All	n/a	52	37	37	3.604	3.032
CYCLE 10 DAY 1	All	n/a	11	7	7	8.333	3.004
CYCLE 12 DAY 1	All	n/a	11	9	9	9.259	3.299
CYCLE 14 DAY 1	All	n/a	11	8	8	6.250	4.221
CYCLE 16 DAY 1	All	n/a	11	6	6	11.111	2.953
INITIAL TREATMENT COMP OR DISC	All	n/a	66	47	47	3.546	3.315

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_QLPRO_B11E_C30QL.xls
 11APR2022 19:50

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Role Functioning
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	82	82	0	NE	NE
CYCLE 2 DAY 1	All	n/a	82	80	80	-10.625	2.770
CYCLE 4 DAY 1	All	n/a	76	75	75	1.111	2.428
CYCLE 6 DAY 1	All	n/a	66	64	64	1.302	2.116
CYCLE 8 DAY 1	All	n/a	64	59	59	-3.107	2.372
CYCLE 10 DAY 1	All	n/a	15	13	13	1.282	5.682
CYCLE 12 DAY 1	All	n/a	13	11	11	1.515	7.149
CYCLE 14 DAY 1	All	n/a	12	11	11	0.000	5.293
CYCLE 16 DAY 1	All	n/a	11	8	8	12.500	6.572
INITIAL TREATMENT COMP OR DISC	All	n/a	80	68	68	0.490	2.739

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_RFPRO_B11E_C30RF.xls
 11APR2022 19:52

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: EORTC QLQ-C30: Scale Social Functioning
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	80	80	0	NE	NE
CYCLE 2 DAY 1	All	n/a	80	77	77	-7.792	2.537
CYCLE 4 DAY 1	All	n/a	74	71	71	5.399	2.080
CYCLE 6 DAY 1	All	n/a	64	61	61	5.464	2.456
CYCLE 8 DAY 1	All	n/a	62	55	55	1.515	3.041
CYCLE 10 DAY 1	All	n/a	14	13	13	2.564	5.123
CYCLE 12 DAY 1	All	n/a	13	11	11	3.030	6.771
CYCLE 14 DAY 1	All	n/a	12	11	11	6.061	5.932
CYCLE 16 DAY 1	All	n/a	11	8	8	8.333	7.595
INITIAL TREATMENT COMP OR DISC	All	n/a	78	66	66	2.778	2.872

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_SFPRO_B11E_C30SF.xls
 11APR2022 19:53

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=80)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	80	100.0	43	53.8	37	46.3	0.8	0.7	2.1	5.1	2.1	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_CFPRO_B11E_M10C30CF.xls
11APR2022 15:30

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=80)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	80	100.0	43	53.8	37	46.3	0.8	0.7	2.1	5.1	2.1	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_CFPRO_B11E_M15C30CF.xls
11APR2022 15:43

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=80)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	80	100.0	27	33.8	53	66.3	4.9	2.1	6.4	12.0	6.4	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_EFPRO_B11E_M10C30EF.xls
11APR2022 15:29

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=80)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	80	100.0	27	33.8	53	66.3	4.9	2.1	6.4	12.0	6.4	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_EFPRO_B11E_M15C30EF.xls
11APR2022 15:43

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	36	43.9	46	56.1	2.2	2.1	4.9	7.7	5.6	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_PFFPRO_B11E_M10C30PF.xls
11APR2022 15:24

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	21	25.6	61	74.4	5.6	3.5	NE	NE	8.3	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_PFFPRO_B11E_M15C30PF.xls
11APR2022 15:39

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Global Health Status (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=68)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	68	100.0	31	45.6	37	54.4	0.9	0.8	2.5	NE	3.5	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_QLPRO_B11E_M10C30QL.xls
11APR2022 15:22

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Global Health Status (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=68)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	68	100.0	31	45.6	37	54.4	0.9	0.8	2.5	NE	3.5	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_QLPRO_B11E_M15C30QL.xls
11APR2022 15:38

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	48	58.5	34	41.5	0.7	0.7	0.8	3.5	1.0	5.7

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_RFPRO_B11E_M10C30RF.xls
11APR2022 15:28

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=82)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	82	100.0	48	58.5	34	41.5	0.7	0.7	0.8	3.5	1.0	5.7

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_RFPRO_B11E_M15C30RF.xls
11APR2022 15:42

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning (MID 10, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=80)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	80	100.0	42	52.5	38	47.5	0.7	0.7	0.8	5.6	1.0	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_SFPRO_B11E_M10C30SF.xls
11APR2022 15:30

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning (MID 15, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=80)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	80	100.0	42	52.5	38	47.5	0.7	0.7	0.8	5.6	1.0	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_SFPRO_B11E_M15C30SF.xls
11APR2022 15:44


POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients

ENDPOINT: FACT-Lym Subscale Score

MODEL: --

STUDY: GO29781


Plot of Mean and 95% CI by Visit



Init Treat Comp Or Disc - Initial Treatment Completed or Discontinued
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_mean_JAN22_EE_B11E_FLYM.pdf
11APR2022 14:29

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: FACT-Lym Subscale Score (MID 3, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)




Patients at risk															
B11 Exp 3L FL (RP2D)	81	53	52	47	42	36	15	9	9	8	7	7	2	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	1	1	3	5	10	30	34	34	35	36	36	40	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_FLPRO_B11E_M3FLYM.pdf
11APR2022 16:02

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: FACT-Lym Subscale Score (MID 9, worsening)
MODEL: --
STUDY: GO29781
Kaplan-Meier plot of time to first event (months)



Patients at risk															
B11 Exp 3L FL (RP2D)	81	69	65	61	56	50	19	11	11	10	9	8	4	NE	NE
Patients censored															
B11 Exp 3L FL (RP2D)	0	2	5	9	13	19	49	56	56	57	58	59	63	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/eff_g_tte_JAN22_FLPRO_B11E_M9FLYM.pdf
11APR2022 16:24

POPULATION: Cohort B11 Expansion FL, Efficacy-Evaluable Patients
ENDPOINT: FACT-Lym Subscale Score
MODEL: --
STUDY: GO29781
Compliance/Mean

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients				Statistics	
Name	Level	in study ¹	%	with value ¹	%	mean ²	SD
All							
BASELINE	n/a	90	100.0	84	93.3	47.10	8.93
CYCLE 2 DAY 1	n/a	87	96.7	80	92.0	47.08	8.52
CYCLE 4 DAY 1	n/a	81	90.0	77	95.1	50.55	7.13
CYCLE 6 DAY 1	n/a	71	78.9	68	95.8	51.41	7.61
CYCLE 8 DAY 1	n/a	69	76.7	63	91.3	50.45	8.06
CYCLE 10 DAY 1	n/a	15	16.7	13	86.7	48.62	6.80
CYCLE 12 DAY 1	n/a	13	14.4	11	84.6	49.79	7.74
CYCLE 14 DAY 1	n/a	12	13.3	11	91.7	48.27	8.78
CYCLE 16 DAY 1	n/a	11	12.2	8	72.7	50.88	8.56
INITIAL TREATMENT COMP OR DISC	n/a	88	97.8	70	79.5	50.02	8.28

¹ in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
² mean: descriptive statistics - absolute values
Clinical cut-off: 03JAN2022

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
 ENDPOINT: FACT-Lym Subscale Score
 MODEL: --
 STUDY: GO29781
 Change from Baseline, Analysis of MMRM

			Patients			Statistics	
Endpoint	Name	Level	Total	with baseline value	included in analysis ¹	LSMeans ²	SE (LSMeans)
BASELINE	All	n/a	81	81	0	NE	NE
CYCLE 2 DAY 1	All	n/a	81	77	77	-1.055	0.737
CYCLE 4 DAY 1	All	n/a	75	73	73	2.690	0.610
CYCLE 6 DAY 1	All	n/a	66	64	64	2.749	0.770
CYCLE 8 DAY 1	All	n/a	64	59	59	1.644	0.867
CYCLE 10 DAY 1	All	n/a	15	13	13	2.308	0.926
CYCLE 12 DAY 1	All	n/a	13	11	11	3.422	0.790
CYCLE 14 DAY 1	All	n/a	12	11	11	3.091	1.465
CYCLE 16 DAY 1	All	n/a	11	8	8	4.250	1.938
INITIAL TREATMENT COMP OR DISC	All	n/a	79	67	67	1.846	0.934

¹ Patients with a value at baseline and at least one post-baseline value.

² LSMeans of change from baseline from MMRM (including all available records from all visits).

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_mmrn.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_mmrn_JAN22_FLPRO_B11E_FLYM.xls
 11APR2022 19:53

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: FACT-Lym Subscale Score (MID 3, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=81)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	81	100.0	39	48.1	42	51.9	0.8	0.7	2.1	6.6	3.3	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_FLPRO_B11E_M3FLYM.xls
11APR2022 15:32

POPULATION: Cohort B11 Expansion FL, PRO-Evaluable Patients
ENDPOINT: FACT-Lym Subscale Score (MID 9, worsening)
MODEL: --
STUDY: GO29781
Time to event analysis (efficacy)

		B11 Exp 3L FL (RP2D) (N=81)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	81	100.0	14	17.3	67	82.7	NE	5.6	NE	NE	NE	NE

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/eff_tte_JAN22_FLPRO_B11E_M9FLYM.xls
11APR2022 15:46

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: Any AEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	90	100.0	95.9	100.0

95% CI based on Wilson Scores.
All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_MNP_AEANY.xls
04MAR2022 8:55

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients

ENDPOINT: Any AEs

MODEL: --

STUDY: GO29781

Dichotomous analysis (safety)

				B11 Exp 3L FL (RP2D) (N=90)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	Blood and lymphatic system disorders	-Total	n/a	90	100.0	27	30.0	21.5	40.1
		Anaemia	n/a	90	100.0	12	13.3	7.8	21.9
		Leukopenia	n/a	90	100.0	2	2.2	0.6	7.7
		Lymph node pain	n/a	90	100.0	1	1.1	0.2	6.0
		Lymphadenopathy	n/a	90	100.0	1	1.1	0.2	6.0
		Lymphopenia	n/a	90	100.0	4	4.4	1.7	10.9
		Neutropenia	n/a	90	100.0	18	20.0	13.0	29.4
		Thrombocytopenia	n/a	90	100.0	6	6.7	3.1	13.8
	Cardiac disorders	-Total	n/a	90	100.0	10	11.1	6.1	19.3
		Bradycardia	n/a	90	100.0	1	1.1	0.2	6.0
		Cardiovascular insufficiency	n/a	90	100.0	1	1.1	0.2	6.0
		Palpitations	n/a	90	100.0	2	2.2	0.6	7.7
		Sinus tachycardia	n/a	90	100.0	3	3.3	1.1	9.3
		Stress cardiomyopathy	n/a	90	100.0	1	1.1	0.2	6.0
		Tachycardia	n/a	90	100.0	2	2.2	0.6	7.7
	Ear and labyrinth disorders	-Total	n/a	90	100.0	4	4.4	1.7	10.9
		Hyperacusis	n/a	90	100.0	1	1.1	0.2	6.0
		Tinnitus	n/a	90	100.0	1	1.1	0.2	6.0
		Vertigo	n/a	90	100.0	2	2.2	0.6	7.7
	Endocrine disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Cushingoid	n/a	90	100.0	1	1.1	0.2	6.0
		Endocrine disorder	n/a	90	100.0	1	1.1	0.2	6.0

	Eye disorders	-Total	n/a	90	100.0	12	13.3	7.8	21.9
		Cataract	n/a	90	100.0	1	1.1	0.2	6.0
		Eye irritation	n/a	90	100.0	2	2.2	0.6	7.7
		Eye pain	n/a	90	100.0	2	2.2	0.6	7.7
		Lacrimation increased	n/a	90	100.0	1	1.1	0.2	6.0
		Ocular hyperaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Periorbital oedema	n/a	90	100.0	2	2.2	0.6	7.7
		Periorbital swelling	n/a	90	100.0	1	1.1	0.2	6.0
		Presbyopia	n/a	90	100.0	1	1.1	0.2	6.0
		Vision blurred	n/a	90	100.0	2	2.2	0.6	7.7
		Vitreous floaters	n/a	90	100.0	1	1.1	0.2	6.0
	Gastrointestinal disorders	-Total	n/a	90	100.0	52	57.8	47.5	67.5
		Abdominal discomfort	n/a	90	100.0	1	1.1	0.2	6.0
		Abdominal distension	n/a	90	100.0	2	2.2	0.6	7.7
		Abdominal pain	n/a	90	100.0	9	10.0	5.4	17.9
		Abdominal pain lower	n/a	90	100.0	1	1.1	0.2	6.0
		Ascites	n/a	90	100.0	3	3.3	1.1	9.3
		Constipation	n/a	90	100.0	15	16.7	10.4	25.7
		Dental caries	n/a	90	100.0	1	1.1	0.2	6.0
		Diarrhoea	n/a	90	100.0	15	16.7	10.4	25.7
		Dry mouth	n/a	90	100.0	2	2.2	0.6	7.7
		Dyspepsia	n/a	90	100.0	6	6.7	3.1	13.8
		Flatulence	n/a	90	100.0	2	2.2	0.6	7.7
		Gastritis	n/a	90	100.0	1	1.1	0.2	6.0
		Gastrointestinal haemorrhage	n/a	90	100.0	1	1.1	0.2	6.0
		Gastrooesophageal reflux disease	n/a	90	100.0	5	5.6	2.4	12.4
		Gingival pain	n/a	90	100.0	1	1.1	0.2	6.0
		Haemorrhoids	n/a	90	100.0	2	2.2	0.6	7.7

		Lip swelling	n/a	90	100.0	1	1.1	0.2	6.0
		Lip ulceration	n/a	90	100.0	1	1.1	0.2	6.0
		Mouth ulceration	n/a	90	100.0	2	2.2	0.6	7.7
		Nausea	n/a	90	100.0	15	16.7	10.4	25.7
		Obstruction gastric	n/a	90	100.0	1	1.1	0.2	6.0
		Oral discomfort	n/a	90	100.0	1	1.1	0.2	6.0
		Stomatitis	n/a	90	100.0	2	2.2	0.6	7.7
		Vomiting	n/a	90	100.0	8	8.9	4.6	16.6
	General disorders and administration site conditions	-Total	n/a	90	100.0	58	64.4	54.2	73.6
		Asthenia	n/a	90	100.0	4	4.4	1.7	10.9
		Axillary pain	n/a	90	100.0	1	1.1	0.2	6.0
		Chest discomfort	n/a	90	100.0	2	2.2	0.6	7.7
		Chest pain	n/a	90	100.0	3	3.3	1.1	9.3
		Chills	n/a	90	100.0	12	13.3	7.8	21.9
		Death	n/a	90	100.0	1	1.1	0.2	6.0
		Face oedema	n/a	90	100.0	2	2.2	0.6	7.7
		Fatigue	n/a	90	100.0	33	36.7	27.4	47.0
		Feeling hot	n/a	90	100.0	1	1.1	0.2	6.0
		Gait disturbance	n/a	90	100.0	1	1.1	0.2	6.0
		Influenza like illness	n/a	90	100.0	3	3.3	1.1	9.3
		Localised oedema	n/a	90	100.0	1	1.1	0.2	6.0
		Malaise	n/a	90	100.0	1	1.1	0.2	6.0
		Non-cardiac chest pain	n/a	90	100.0	2	2.2	0.6	7.7
		Oedema	n/a	90	100.0	1	1.1	0.2	6.0
		Oedema peripheral	n/a	90	100.0	10	11.1	6.1	19.3
		Pain	n/a	90	100.0	5	5.6	2.4	12.4
		Peripheral swelling	n/a	90	100.0	2	2.2	0.6	7.7
		Physical deconditioning	n/a	90	100.0	1	1.1	0.2	6.0

		Pyrexia	n/a	90	100.0	26	28.9	20.5	39.0
		Swelling	n/a	90	100.0	1	1.1	0.2	6.0
		Swelling face	n/a	90	100.0	1	1.1	0.2	6.0
	Hepatobiliary disorders	-Total	n/a	90	100.0	4	4.4	1.7	10.9
		Cholangitis	n/a	90	100.0	1	1.1	0.2	6.0
		Cholecystitis acute	n/a	90	100.0	1	1.1	0.2	6.0
		Gallbladder polyp	n/a	90	100.0	1	1.1	0.2	6.0
		Hepatic function abnormal	n/a	90	100.0	1	1.1	0.2	6.0
		Hypertransaminaemia	n/a	90	100.0	1	1.1	0.2	6.0
	Immune system disorders	-Total	n/a	90	100.0	41	45.6	35.7	55.8
		Cytokine release syndrome	n/a	90	100.0	41	45.6	35.7	55.8
		Hypersensitivity	n/a	90	100.0	1	1.1	0.2	6.0
		Hypogammaglobulinaemia	n/a	90	100.0	2	2.2	0.6	7.7
	Infections and infestations	-Total	n/a	90	100.0	46	51.1	41.0	61.2
		Anorectal infection	n/a	90	100.0	1	1.1	0.2	6.0
		Bronchitis	n/a	90	100.0	3	3.3	1.1	9.3
		COVID-19	n/a	90	100.0	3	3.3	1.1	9.3
		Cellulitis	n/a	90	100.0	3	3.3	1.1	9.3
		Conjunctivitis	n/a	90	100.0	1	1.1	0.2	6.0
		Enterocolitis bacterial	n/a	90	100.0	1	1.1	0.2	6.0
		Epstein-Barr viraemia	n/a	90	100.0	2	2.2	0.6	7.7
		Gastroenteritis	n/a	90	100.0	1	1.1	0.2	6.0
		Giardiasis	n/a	90	100.0	1	1.1	0.2	6.0
		Herpes simplex reactivation	n/a	90	100.0	1	1.1	0.2	6.0
		Herpes zoster	n/a	90	100.0	3	3.3	1.1	9.3
		Infection	n/a	90	100.0	1	1.1	0.2	6.0
		Klebsiella infection	n/a	90	100.0	2	2.2	0.6	7.7
		Nail infection	n/a	90	100.0	1	1.1	0.2	6.0

		Nasopharyngitis	n/a	90	100.0	3	3.3	1.1	9.3
		Oesophageal infection	n/a	90	100.0	1	1.1	0.2	6.0
		Oral candidiasis	n/a	90	100.0	2	2.2	0.6	7.7
		Oral fungal infection	n/a	90	100.0	1	1.1	0.2	6.0
		Oral herpes	n/a	90	100.0	2	2.2	0.6	7.7
		Paronychia	n/a	90	100.0	2	2.2	0.6	7.7
		Pneumocystis jirovecii pneumonia	n/a	90	100.0	1	1.1	0.2	6.0
		Pneumonia	n/a	90	100.0	5	5.6	2.4	12.4
		Pneumonia mycoplasmal	n/a	90	100.0	1	1.1	0.2	6.0
		Pustule	n/a	90	100.0	1	1.1	0.2	6.0
		Pyelonephritis acute	n/a	90	100.0	1	1.1	0.2	6.0
		Rash pustular	n/a	90	100.0	2	2.2	0.6	7.7
		Rhinovirus infection	n/a	90	100.0	2	2.2	0.6	7.7
		Sepsis	n/a	90	100.0	1	1.1	0.2	6.0
		Septic shock	n/a	90	100.0	2	2.2	0.6	7.7
		Sinusitis	n/a	90	100.0	3	3.3	1.1	9.3
		Staphylococcal bacteraemia	n/a	90	100.0	1	1.1	0.2	6.0
		Suspected COVID-19	n/a	90	100.0	1	1.1	0.2	6.0
		Tinea cruris	n/a	90	100.0	1	1.1	0.2	6.0
		Tinea pedis	n/a	90	100.0	2	2.2	0.6	7.7
		Upper respiratory tract infection	n/a	90	100.0	8	8.9	4.6	16.6
		Urinary tract infection	n/a	90	100.0	8	8.9	4.6	16.6
		Varicella zoster virus infection	n/a	90	100.0	1	1.1	0.2	6.0
	Injury, poisoning and procedural complications	-Total	n/a	90	100.0	13	14.4	8.6	23.2
		Contusion	n/a	90	100.0	2	2.2	0.6	7.7
		Fall	n/a	90	100.0	3	3.3	1.1	9.3
		Fracture	n/a	90	100.0	1	1.1	0.2	6.0
		Hip fracture	n/a	90	100.0	1	1.1	0.2	6.0

		Infusion related reaction	n/a	90	100.0	1	1.1	0.2	6.0
		Muscle strain	n/a	90	100.0	1	1.1	0.2	6.0
		Skin laceration	n/a	90	100.0	1	1.1	0.2	6.0
		Subdural haematoma	n/a	90	100.0	1	1.1	0.2	6.0
		Transfusion reaction	n/a	90	100.0	1	1.1	0.2	6.0
		Vascular access complication	n/a	90	100.0	1	1.1	0.2	6.0
	Investigations	-Total	n/a	90	100.0	33	36.7	27.4	47.0
		Alanine aminotransferase increased	n/a	90	100.0	11	12.2	7.0	20.6
		Aspartate aminotransferase increased	n/a	90	100.0	5	5.6	2.4	12.4
		Blood alkaline phosphatase increased	n/a	90	100.0	2	2.2	0.6	7.7
		Blood bilirubin increased	n/a	90	100.0	1	1.1	0.2	6.0
		Blood creatinine increased	n/a	90	100.0	8	8.9	4.6	16.6
		Blood fibrinogen decreased	n/a	90	100.0	1	1.1	0.2	6.0
		Blood lactate dehydrogenase increased	n/a	90	100.0	2	2.2	0.6	7.7
		Blood phosphorus decreased	n/a	90	100.0	1	1.1	0.2	6.0
		Blood uric acid increased	n/a	90	100.0	1	1.1	0.2	6.0
		C-reactive protein increased	n/a	90	100.0	4	4.4	1.7	10.9
		Cardiac murmur	n/a	90	100.0	1	1.1	0.2	6.0
		Coronavirus test negative	n/a	90	100.0	1	1.1	0.2	6.0
		Electrocardiogram QT prolonged	n/a	90	100.0	1	1.1	0.2	6.0
		Enterococcus test positive	n/a	90	100.0	1	1.1	0.2	6.0
		Epstein-Barr virus test positive	n/a	90	100.0	1	1.1	0.2	6.0
		Gamma-glutamyltransferase increased	n/a	90	100.0	3	3.3	1.1	9.3
		Hepatic enzyme increased	n/a	90	100.0	1	1.1	0.2	6.0
		Human rhinovirus test positive	n/a	90	100.0	1	1.1	0.2	6.0
		Immunoglobulins decreased	n/a	90	100.0	1	1.1	0.2	6.0
		Lymphocyte count decreased	n/a	90	100.0	1	1.1	0.2	6.0
		Neutrophil count decreased	n/a	90	100.0	8	8.9	4.6	16.6

		Platelet count decreased	n/a	90	100.0	3	3.3	1.1	9.3
		Pseudomonas test positive	n/a	90	100.0	1	1.1	0.2	6.0
		Respiratory syncytial virus test positive	n/a	90	100.0	1	1.1	0.2	6.0
		Serum ferritin decreased	n/a	90	100.0	2	2.2	0.6	7.7
		Weight increased	n/a	90	100.0	2	2.2	0.6	7.7
	Metabolism and nutrition disorders	-Total	n/a	90	100.0	49	54.4	44.2	64.3
		Decreased appetite	n/a	90	100.0	6	6.7	3.1	13.8
		Dehydration	n/a	90	100.0	2	2.2	0.6	7.7
		Dyslipidaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Fluid retention	n/a	90	100.0	1	1.1	0.2	6.0
		Hypercalcaemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hyperglycaemia	n/a	90	100.0	8	8.9	4.6	16.6
		Hypernatraemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hyperphosphataemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hyperuricaemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hypervolaemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hypoalbuminaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypocalcaemia	n/a	90	100.0	3	3.3	1.1	9.3
		Hypoglycaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypokalaemia	n/a	90	100.0	17	18.9	12.1	28.2
		Hypomagnesaemia	n/a	90	100.0	11	12.2	7.0	20.6
		Hyponatraemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypophosphataemia	n/a	90	100.0	24	26.7	18.6	36.6
		Hypovolaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Iron deficiency	n/a	90	100.0	1	1.1	0.2	6.0
		Malnutrition	n/a	90	100.0	1	1.1	0.2	6.0
		Tumour lysis syndrome	n/a	90	100.0	1	1.1	0.2	6.0
		Vitamin D deficiency	n/a	90	100.0	1	1.1	0.2	6.0

	Musculoskeletal and connective tissue disorders	-Total	n/a	90	100.0	37	41.1	31.5	51.4
		Arthralgia	n/a	90	100.0	11	12.2	7.0	20.6
		Arthritis	n/a	90	100.0	1	1.1	0.2	6.0
		Back pain	n/a	90	100.0	9	10.0	5.4	17.9
		Bone pain	n/a	90	100.0	6	6.7	3.1	13.8
		Joint swelling	n/a	90	100.0	1	1.1	0.2	6.0
		Metatarsalgia	n/a	90	100.0	1	1.1	0.2	6.0
		Muscle spasms	n/a	90	100.0	1	1.1	0.2	6.0
		Muscular weakness	n/a	90	100.0	1	1.1	0.2	6.0
		Musculoskeletal chest pain	n/a	90	100.0	4	4.4	1.7	10.9
		Musculoskeletal pain	n/a	90	100.0	2	2.2	0.6	7.7
		Myalgia	n/a	90	100.0	8	8.9	4.6	16.6
		Neck pain	n/a	90	100.0	3	3.3	1.1	9.3
		Osteoarthritis	n/a	90	100.0	1	1.1	0.2	6.0
		Osteoporosis	n/a	90	100.0	2	2.2	0.6	7.7
		Pain in extremity	n/a	90	100.0	4	4.4	1.7	10.9
		Rotator cuff syndrome	n/a	90	100.0	1	1.1	0.2	6.0
		Sacral pain	n/a	90	100.0	1	1.1	0.2	6.0
		Spinal stenosis	n/a	90	100.0	1	1.1	0.2	6.0
		Tendon pain	n/a	90	100.0	1	1.1	0.2	6.0
		Tendonitis	n/a	90	100.0	1	1.1	0.2	6.0
		Trismus	n/a	90	100.0	1	1.1	0.2	6.0
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	-Total	n/a	90	100.0	8	8.9	4.6	16.6
		Hodgkin's disease	n/a	90	100.0	1	1.1	0.2	6.0
		Squamous cell carcinoma	n/a	90	100.0	2	2.2	0.6	7.7
		Tumour flare	n/a	90	100.0	2	2.2	0.6	7.7
		Tumour pain	n/a	90	100.0	3	3.3	1.1	9.3
	Nervous system disorders	-Total	n/a	90	100.0	49	54.4	44.2	64.3

		Allodynia	n/a	90	100.0	1	1.1	0.2	6.0
		Ataxia	n/a	90	100.0	1	1.1	0.2	6.0
		Burning sensation	n/a	90	100.0	1	1.1	0.2	6.0
		Cognitive disorder	n/a	90	100.0	1	1.1	0.2	6.0
		Disturbance in attention	n/a	90	100.0	1	1.1	0.2	6.0
		Dizziness	n/a	90	100.0	9	10.0	5.4	17.9
		Dysaesthesia	n/a	90	100.0	1	1.1	0.2	6.0
		Dysgeusia	n/a	90	100.0	3	3.3	1.1	9.3
		Head discomfort	n/a	90	100.0	1	1.1	0.2	6.0
		Headache	n/a	90	100.0	28	31.1	22.5	41.3
		Hypoaesthesia	n/a	90	100.0	1	1.1	0.2	6.0
		Lethargy	n/a	90	100.0	2	2.2	0.6	7.7
		Migraine	n/a	90	100.0	1	1.1	0.2	6.0
		Neuralgia	n/a	90	100.0	1	1.1	0.2	6.0
		Neuropathy peripheral	n/a	90	100.0	5	5.6	2.4	12.4
		Paraesthesia	n/a	90	100.0	5	5.6	2.4	12.4
		Peripheral sensory neuropathy	n/a	90	100.0	5	5.6	2.4	12.4
		Presyncope	n/a	90	100.0	3	3.3	1.1	9.3
		Sciatica	n/a	90	100.0	1	1.1	0.2	6.0
		Taste disorder	n/a	90	100.0	1	1.1	0.2	6.0
		Tremor	n/a	90	100.0	1	1.1	0.2	6.0
	Psychiatric disorders	-Total	n/a	90	100.0	21	23.3	15.8	33.1
		Anxiety	n/a	90	100.0	4	4.4	1.7	10.9
		Confusional state	n/a	90	100.0	3	3.3	1.1	9.3
		Depression	n/a	90	100.0	3	3.3	1.1	9.3
		Fear	n/a	90	100.0	1	1.1	0.2	6.0
		Insomnia	n/a	90	100.0	11	12.2	7.0	20.6
		Mixed anxiety and depressive disorder	n/a	90	100.0	1	1.1	0.2	6.0

		Mood altered	n/a	90	100.0	1	1.1	0.2	6.0
		Restlessness	n/a	90	100.0	1	1.1	0.2	6.0
	Renal and urinary disorders	-Total	n/a	90	100.0	9	10.0	5.4	17.9
		Acute kidney injury	n/a	90	100.0	5	5.6	2.4	12.4
		Dysuria	n/a	90	100.0	1	1.1	0.2	6.0
		Pollakiuria	n/a	90	100.0	2	2.2	0.6	7.7
		Urinary hesitation	n/a	90	100.0	1	1.1	0.2	6.0
		Urinary incontinence	n/a	90	100.0	1	1.1	0.2	6.0
	Reproductive system and breast disorders	-Total	n/a	90	100.0	4	4.4	1.7	10.9
		Pruritus genital	n/a	90	100.0	1	1.1	0.2	6.0
		Scrotal swelling	n/a	90	100.0	1	1.1	0.2	6.0
		Uterine haemorrhage	n/a	90	100.0	1	1.1	0.2	6.0
		Vulvovaginal dryness	n/a	90	100.0	1	1.1	0.2	6.0
	Respiratory, thoracic and mediastinal disorders	-Total	n/a	90	100.0	40	44.4	34.6	54.7
		Cough	n/a	90	100.0	16	17.8	11.2	26.9
		Dyspnoea	n/a	90	100.0	7	7.8	3.8	15.2
		Dyspnoea exertional	n/a	90	100.0	3	3.3	1.1	9.3
		Eosinophilic bronchitis	n/a	90	100.0	1	1.1	0.2	6.0
		Epistaxis	n/a	90	100.0	2	2.2	0.6	7.7
		Hiccups	n/a	90	100.0	1	1.1	0.2	6.0
		Hypoxia	n/a	90	100.0	1	1.1	0.2	6.0
		Laryngeal inflammation	n/a	90	100.0	1	1.1	0.2	6.0
		Laryngeal oedema	n/a	90	100.0	1	1.1	0.2	6.0
		Nasal congestion	n/a	90	100.0	7	7.8	3.8	15.2
		Nasal ulcer	n/a	90	100.0	1	1.1	0.2	6.0
		Oropharyngeal pain	n/a	90	100.0	6	6.7	3.1	13.8
		Pleural effusion	n/a	90	100.0	4	4.4	1.7	10.9
		Pneumonitis	n/a	90	100.0	1	1.1	0.2	6.0

		Productive cough	n/a	90	100.0	5	5.6	2.4	12.4
		Pulmonary embolism	n/a	90	100.0	1	1.1	0.2	6.0
		Pulmonary oedema	n/a	90	100.0	1	1.1	0.2	6.0
		Rhinitis allergic	n/a	90	100.0	1	1.1	0.2	6.0
		Rhinorrhoea	n/a	90	100.0	2	2.2	0.6	7.7
		Stridor	n/a	90	100.0	1	1.1	0.2	6.0
		Throat irritation	n/a	90	100.0	1	1.1	0.2	6.0
		Upper-airway cough syndrome	n/a	90	100.0	2	2.2	0.6	7.7
		Wheezing	n/a	90	100.0	3	3.3	1.1	9.3
	Skin and subcutaneous tissue disorders	-Total	n/a	90	100.0	58	64.4	54.2	73.6
		Actinic keratosis	n/a	90	100.0	1	1.1	0.2	6.0
		Alopecia	n/a	90	100.0	2	2.2	0.6	7.7
		Cold sweat	n/a	90	100.0	1	1.1	0.2	6.0
		Dermatitis	n/a	90	100.0	1	1.1	0.2	6.0
		Dermatitis acneiform	n/a	90	100.0	2	2.2	0.6	7.7
		Dry skin	n/a	90	100.0	14	15.6	9.5	24.4
		Dyshidrotic eczema	n/a	90	100.0	1	1.1	0.2	6.0
		Eczema	n/a	90	100.0	2	2.2	0.6	7.7
		Erythema	n/a	90	100.0	8	8.9	4.6	16.6
		Exfoliative rash	n/a	90	100.0	1	1.1	0.2	6.0
		Hyperhidrosis	n/a	90	100.0	6	6.7	3.1	13.8
		Nail disorder	n/a	90	100.0	1	1.1	0.2	6.0
		Night sweats	n/a	90	100.0	2	2.2	0.6	7.7
		Onychoclasia	n/a	90	100.0	1	1.1	0.2	6.0
		Palmar erythema	n/a	90	100.0	2	2.2	0.6	7.7
		Pruritus	n/a	90	100.0	19	21.1	14.0	30.6
		Rash	n/a	90	100.0	14	15.6	9.5	24.4
		Rash erythematous	n/a	90	100.0	7	7.8	3.8	15.2

		Rash macular	n/a	90	100.0	1	1.1	0.2	6.0
		Rash maculo-papular	n/a	90	100.0	3	3.3	1.1	9.3
		Rash papular	n/a	90	100.0	2	2.2	0.6	7.7
		Rash pruritic	n/a	90	100.0	3	3.3	1.1	9.3
		Sebaceous hyperplasia	n/a	90	100.0	1	1.1	0.2	6.0
		Skin disorder	n/a	90	100.0	1	1.1	0.2	6.0
		Skin exfoliation	n/a	90	100.0	9	10.0	5.4	17.9
		Skin fissures	n/a	90	100.0	1	1.1	0.2	6.0
		Skin lesion	n/a	90	100.0	1	1.1	0.2	6.0
		Skin plaque	n/a	90	100.0	1	1.1	0.2	6.0
		Skin tightness	n/a	90	100.0	1	1.1	0.2	6.0
		Urticaria	n/a	90	100.0	5	5.6	2.4	12.4
		Vitiligo	n/a	90	100.0	1	1.1	0.2	6.0
	Vascular disorders	-Total	n/a	90	100.0	17	18.9	12.1	28.2
		Deep vein thrombosis	n/a	90	100.0	2	2.2	0.6	7.7
		Flushing	n/a	90	100.0	7	7.8	3.8	15.2
		Hot flush	n/a	90	100.0	2	2.2	0.6	7.7
		Hypertension	n/a	90	100.0	1	1.1	0.2	6.0
		Hypotension	n/a	90	100.0	4	4.4	1.7	10.9
		Orthostatic hypotension	n/a	90	100.0	1	1.1	0.2	6.0
		Phlebitis	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.

All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/saf_raw_soc_JAN22_SE_B11E_MNP_AEANY.xls

04MAR2022 9:00

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
 ENDPOINT: AEs Grade >=2
 MODEL: --
 STUDY: GO29781
 Dichotomous analysis (safety)

				B11 Exp 3L FL (RP2D) (N=90)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	Blood and lymphatic system disorders	-Total	n/a	90	100.0	25	27.8	19.6	37.8
		Anaemia	n/a	90	100.0	9	10.0	5.4	17.9
		Leukopenia	n/a	90	100.0	2	2.2	0.6	7.7
		Lymphadenopathy	n/a	90	100.0	1	1.1	0.2	6.0
		Lymphopenia	n/a	90	100.0	4	4.4	1.7	10.9
		Neutropenia	n/a	90	100.0	17	18.9	12.1	28.2
		Thrombocytopenia	n/a	90	100.0	3	3.3	1.1	9.3
	Endocrine disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Endocrine disorder	n/a	90	100.0	1	1.1	0.2	6.0
	Eye disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Cataract	n/a	90	100.0	1	1.1	0.2	6.0
		Lacrimation increased	n/a	90	100.0	1	1.1	0.2	6.0
	Gastrointestinal disorders	-Total	n/a	90	100.0	17	18.9	12.1	28.2
		Abdominal discomfort	n/a	90	100.0	1	1.1	0.2	6.0
		Abdominal pain	n/a	90	100.0	3	3.3	1.1	9.3
		Ascites	n/a	90	100.0	2	2.2	0.6	7.7
		Constipation	n/a	90	100.0	3	3.3	1.1	9.3
		Diarrhoea	n/a	90	100.0	3	3.3	1.1	9.3
		Dry mouth	n/a	90	100.0	1	1.1	0.2	6.0
		Dyspepsia	n/a	90	100.0	3	3.3	1.1	9.3
		Flatulence	n/a	90	100.0	1	1.1	0.2	6.0
		Gastritis	n/a	90	100.0	1	1.1	0.2	6.0

		Gastrooesophageal reflux disease	n/a	90	100.0	2	2.2	0.6	7.7
		Haemorrhoids	n/a	90	100.0	1	1.1	0.2	6.0
		Nausea	n/a	90	100.0	1	1.1	0.2	6.0
		Obstruction gastric	n/a	90	100.0	1	1.1	0.2	6.0
		Stomatitis	n/a	90	100.0	1	1.1	0.2	6.0
		Vomiting	n/a	90	100.0	1	1.1	0.2	6.0
	General disorders and administration site conditions	-Total	n/a	90	100.0	23	25.6	17.7	35.4
		Asthenia	n/a	90	100.0	1	1.1	0.2	6.0
		Chest pain	n/a	90	100.0	2	2.2	0.6	7.7
		Chills	n/a	90	100.0	1	1.1	0.2	6.0
		Death	n/a	90	100.0	1	1.1	0.2	6.0
		Fatigue	n/a	90	100.0	9	10.0	5.4	17.9
		Influenza like illness	n/a	90	100.0	1	1.1	0.2	6.0
		Oedema peripheral	n/a	90	100.0	6	6.7	3.1	13.8
		Pain	n/a	90	100.0	1	1.1	0.2	6.0
		Physical deconditioning	n/a	90	100.0	1	1.1	0.2	6.0
		Pyrexia	n/a	90	100.0	6	6.7	3.1	13.8
		Swelling face	n/a	90	100.0	1	1.1	0.2	6.0
	Hepatobiliary disorders	-Total	n/a	90	100.0	3	3.3	1.1	9.3
		Cholangitis	n/a	90	100.0	1	1.1	0.2	6.0
		Cholecystitis acute	n/a	90	100.0	1	1.1	0.2	6.0
		Hepatic function abnormal	n/a	90	100.0	1	1.1	0.2	6.0
	Immune system disorders	-Total	n/a	90	100.0	19	21.1	14.0	30.6
		Cytokine release syndrome	n/a	90	100.0	18	20.0	13.0	29.4
		Hypersensitivity	n/a	90	100.0	1	1.1	0.2	6.0
		Hypogammaglobulinaemia	n/a	90	100.0	1	1.1	0.2	6.0
	Infections and infestations	-Total	n/a	90	100.0	35	38.9	29.5	49.2
		Anorectal infection	n/a	90	100.0	1	1.1	0.2	6.0

		COVID-19	n/a	90	100.0	2	2.2	0.6	7.7
		Cellulitis	n/a	90	100.0	3	3.3	1.1	9.3
		Enterocolitis bacterial	n/a	90	100.0	1	1.1	0.2	6.0
		Epstein-Barr viraemia	n/a	90	100.0	2	2.2	0.6	7.7
		Giardiasis	n/a	90	100.0	1	1.1	0.2	6.0
		Herpes simplex reactivation	n/a	90	100.0	1	1.1	0.2	6.0
		Herpes zoster	n/a	90	100.0	3	3.3	1.1	9.3
		Infection	n/a	90	100.0	1	1.1	0.2	6.0
		Klebsiella infection	n/a	90	100.0	2	2.2	0.6	7.7
		Nail infection	n/a	90	100.0	1	1.1	0.2	6.0
		Nasopharyngitis	n/a	90	100.0	2	2.2	0.6	7.7
		Oesophageal infection	n/a	90	100.0	1	1.1	0.2	6.0
		Oral candidiasis	n/a	90	100.0	1	1.1	0.2	6.0
		Oral fungal infection	n/a	90	100.0	1	1.1	0.2	6.0
		Oral herpes	n/a	90	100.0	2	2.2	0.6	7.7
		Pneumocystis jirovecii pneumonia	n/a	90	100.0	1	1.1	0.2	6.0
		Pneumonia	n/a	90	100.0	5	5.6	2.4	12.4
		Pneumonia mycoplasmal	n/a	90	100.0	1	1.1	0.2	6.0
		Pyelonephritis acute	n/a	90	100.0	1	1.1	0.2	6.0
		Rash pustular	n/a	90	100.0	2	2.2	0.6	7.7
		Sepsis	n/a	90	100.0	1	1.1	0.2	6.0
		Septic shock	n/a	90	100.0	2	2.2	0.6	7.7
		Sinusitis	n/a	90	100.0	3	3.3	1.1	9.3
		Staphylococcal bacteraemia	n/a	90	100.0	1	1.1	0.2	6.0
		Upper respiratory tract infection	n/a	90	100.0	7	7.8	3.8	15.2
		Urinary tract infection	n/a	90	100.0	7	7.8	3.8	15.2
		Varicella zoster virus infection	n/a	90	100.0	1	1.1	0.2	6.0
	Injury, poisoning and procedural complications	-Total	n/a	90	100.0	6	6.7	3.1	13.8

		Fall	n/a	90	100.0	1	1.1	0.2	6.0
		Hip fracture	n/a	90	100.0	1	1.1	0.2	6.0
		Skin laceration	n/a	90	100.0	1	1.1	0.2	6.0
		Subdural haematoma	n/a	90	100.0	1	1.1	0.2	6.0
		Transfusion reaction	n/a	90	100.0	1	1.1	0.2	6.0
		Vascular access complication	n/a	90	100.0	1	1.1	0.2	6.0
	Investigations	-Total	n/a	90	100.0	24	26.7	18.6	36.6
		Alanine aminotransferase increased	n/a	90	100.0	7	7.8	3.8	15.2
		Aspartate aminotransferase increased	n/a	90	100.0	4	4.4	1.7	10.9
		Blood alkaline phosphatase increased	n/a	90	100.0	1	1.1	0.2	6.0
		Blood bilirubin increased	n/a	90	100.0	1	1.1	0.2	6.0
		Blood creatinine increased	n/a	90	100.0	3	3.3	1.1	9.3
		Blood fibrinogen decreased	n/a	90	100.0	1	1.1	0.2	6.0
		Blood phosphorus decreased	n/a	90	100.0	1	1.1	0.2	6.0
		C-reactive protein increased	n/a	90	100.0	2	2.2	0.6	7.7
		Electrocardiogram QT prolonged	n/a	90	100.0	1	1.1	0.2	6.0
		Gamma-glutamyltransferase increased	n/a	90	100.0	1	1.1	0.2	6.0
		Hepatic enzyme increased	n/a	90	100.0	1	1.1	0.2	6.0
		Immunoglobulins decreased	n/a	90	100.0	1	1.1	0.2	6.0
		Neutrophil count decreased	n/a	90	100.0	7	7.8	3.8	15.2
		Platelet count decreased	n/a	90	100.0	2	2.2	0.6	7.7
		Respiratory syncytial virus test positive	n/a	90	100.0	1	1.1	0.2	6.0
		Serum ferritin decreased	n/a	90	100.0	2	2.2	0.6	7.7
		Weight increased	n/a	90	100.0	1	1.1	0.2	6.0
	Metabolism and nutrition disorders	-Total	n/a	90	100.0	37	41.1	31.5	51.4
		Dehydration	n/a	90	100.0	1	1.1	0.2	6.0
		Dyslipidaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypercalcaemia	n/a	90	100.0	2	2.2	0.6	7.7

		Hyperglycaemia	n/a	90	100.0	8	8.9	4.6	16.6
		Hyperphosphataemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypervolaemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hypoalbuminaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypocalcaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypoglycaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypokalaemia	n/a	90	100.0	11	12.2	7.0	20.6
		Hypomagnesaemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hyponatraemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypophosphataemia	n/a	90	100.0	24	26.7	18.6	36.6
		Hypovolaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Malnutrition	n/a	90	100.0	1	1.1	0.2	6.0
		Tumour lysis syndrome	n/a	90	100.0	1	1.1	0.2	6.0
		Vitamin D deficiency	n/a	90	100.0	1	1.1	0.2	6.0
	Musculoskeletal and connective tissue disorders	-Total	n/a	90	100.0	11	12.2	7.0	20.6
		Arthralgia	n/a	90	100.0	2	2.2	0.6	7.7
		Back pain	n/a	90	100.0	3	3.3	1.1	9.3
		Bone pain	n/a	90	100.0	2	2.2	0.6	7.7
		Metatarsalgia	n/a	90	100.0	1	1.1	0.2	6.0
		Musculoskeletal pain	n/a	90	100.0	1	1.1	0.2	6.0
		Osteoarthritis	n/a	90	100.0	1	1.1	0.2	6.0
		Osteoporosis	n/a	90	100.0	1	1.1	0.2	6.0
		Pain in extremity	n/a	90	100.0	1	1.1	0.2	6.0
		Spinal stenosis	n/a	90	100.0	1	1.1	0.2	6.0
		Tendon pain	n/a	90	100.0	1	1.1	0.2	6.0
		Tendonitis	n/a	90	100.0	1	1.1	0.2	6.0
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	-Total	n/a	90	100.0	6	6.7	3.1	13.8
		Hodgkin's disease	n/a	90	100.0	1	1.1	0.2	6.0

		Squamous cell carcinoma	n/a	90	100.0	1	1.1	0.2	6.0
		Tumour flare	n/a	90	100.0	2	2.2	0.6	7.7
		Tumour pain	n/a	90	100.0	2	2.2	0.6	7.7
	Nervous system disorders	-Total	n/a	90	100.0	9	10.0	5.4	17.9
		Dysaesthesia	n/a	90	100.0	1	1.1	0.2	6.0
		Dysgeusia	n/a	90	100.0	1	1.1	0.2	6.0
		Headache	n/a	90	100.0	3	3.3	1.1	9.3
		Peripheral sensory neuropathy	n/a	90	100.0	1	1.1	0.2	6.0
		Presyncope	n/a	90	100.0	2	2.2	0.6	7.7
		Sciatica	n/a	90	100.0	1	1.1	0.2	6.0
	Psychiatric disorders	-Total	n/a	90	100.0	9	10.0	5.4	17.9
		Anxiety	n/a	90	100.0	1	1.1	0.2	6.0
		Confusional state	n/a	90	100.0	1	1.1	0.2	6.0
		Depression	n/a	90	100.0	2	2.2	0.6	7.7
		Insomnia	n/a	90	100.0	5	5.6	2.4	12.4
		Mixed anxiety and depressive disorder	n/a	90	100.0	1	1.1	0.2	6.0
	Renal and urinary disorders	-Total	n/a	90	100.0	6	6.7	3.1	13.8
		Acute kidney injury	n/a	90	100.0	5	5.6	2.4	12.4
		Pollakiuria	n/a	90	100.0	1	1.1	0.2	6.0
	Reproductive system and breast disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Scrotal swelling	n/a	90	100.0	1	1.1	0.2	6.0
		Uterine haemorrhage	n/a	90	100.0	1	1.1	0.2	6.0
	Respiratory, thoracic and mediastinal disorders	-Total	n/a	90	100.0	18	20.0	13.0	29.4
		Cough	n/a	90	100.0	3	3.3	1.1	9.3
		Dyspnoea	n/a	90	100.0	4	4.4	1.7	10.9
		Eosinophilic bronchitis	n/a	90	100.0	1	1.1	0.2	6.0
		Epistaxis	n/a	90	100.0	1	1.1	0.2	6.0
		Hiccups	n/a	90	100.0	1	1.1	0.2	6.0

		Hypoxia	n/a	90	100.0	1	1.1	0.2	6.0
		Laryngeal inflammation	n/a	90	100.0	1	1.1	0.2	6.0
		Laryngeal oedema	n/a	90	100.0	1	1.1	0.2	6.0
		Nasal congestion	n/a	90	100.0	3	3.3	1.1	9.3
		Oropharyngeal pain	n/a	90	100.0	1	1.1	0.2	6.0
		Pleural effusion	n/a	90	100.0	3	3.3	1.1	9.3
		Pneumonitis	n/a	90	100.0	1	1.1	0.2	6.0
		Productive cough	n/a	90	100.0	1	1.1	0.2	6.0
		Pulmonary embolism	n/a	90	100.0	1	1.1	0.2	6.0
		Pulmonary oedema	n/a	90	100.0	1	1.1	0.2	6.0
	Skin and subcutaneous tissue disorders	-Total	n/a	90	100.0	23	25.6	17.7	35.4
		Alopecia	n/a	90	100.0	1	1.1	0.2	6.0
		Dermatitis acneiform	n/a	90	100.0	1	1.1	0.2	6.0
		Dry skin	n/a	90	100.0	2	2.2	0.6	7.7
		Dyshidrotic eczema	n/a	90	100.0	1	1.1	0.2	6.0
		Eczema	n/a	90	100.0	1	1.1	0.2	6.0
		Erythema	n/a	90	100.0	1	1.1	0.2	6.0
		Pruritus	n/a	90	100.0	5	5.6	2.4	12.4
		Rash	n/a	90	100.0	5	5.6	2.4	12.4
		Rash erythematous	n/a	90	100.0	5	5.6	2.4	12.4
		Rash macular	n/a	90	100.0	1	1.1	0.2	6.0
		Rash maculo-papular	n/a	90	100.0	1	1.1	0.2	6.0
		Rash papular	n/a	90	100.0	1	1.1	0.2	6.0
		Rash pruritic	n/a	90	100.0	1	1.1	0.2	6.0
		Skin exfoliation	n/a	90	100.0	1	1.1	0.2	6.0
		Skin fissures	n/a	90	100.0	1	1.1	0.2	6.0
		Skin lesion	n/a	90	100.0	1	1.1	0.2	6.0
		Urticaria	n/a	90	100.0	2	2.2	0.6	7.7

	Vascular disorders	-Total	n/a	90	100.0	5	5.6	2.4	12.4
		Deep vein thrombosis	n/a	90	100.0	2	2.2	0.6	7.7
		Hypertension	n/a	90	100.0	1	1.1	0.2	6.0
		Hypotension	n/a	90	100.0	1	1.1	0.2	6.0
		Phlebitis	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.

All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_soc_JAN22_SE_B11E_MNP_AEGR2345.xls

12APR2022 9:31

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AEs Grade >=3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	62	68.9	58.7	77.5

95% CI based on Wilson Scores.
All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_MNP_AEGR345.xls
10MAR2022 14:21

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients

ENDPOINT: AEs Grade ≥3

MODEL: --

STUDY: GO29781

Dichotomous analysis (safety)

				B11 Exp 3L FL (RP2D) (N=90)					
Name	SOC	PT	Level	Patients		Patients with Event			
				n	%	n	%	95% CI (LL)	95% CI (UL)
All	Blood and lymphatic system disorders	-Total	n/a	90	100.0	25	27.8	19.6	37.8
		Anaemia	n/a	90	100.0	7	7.8	3.8	15.2
		Leukopenia	n/a	90	100.0	1	1.1	0.2	6.0
		Lymphopenia	n/a	90	100.0	4	4.4	1.7	10.9
		Neutropenia	n/a	90	100.0	17	18.9	12.1	28.2
		Thrombocytopenia	n/a	90	100.0	3	3.3	1.1	9.3
	Endocrine disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Endocrine disorder	n/a	90	100.0	1	1.1	0.2	6.0
	Eye disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Cataract	n/a	90	100.0	1	1.1	0.2	6.0
	Gastrointestinal disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Abdominal pain	n/a	90	100.0	1	1.1	0.2	6.0
		Ascites	n/a	90	100.0	1	1.1	0.2	6.0
	General disorders and administration site conditions	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Chills	n/a	90	100.0	1	1.1	0.2	6.0
		Death	n/a	90	100.0	1	1.1	0.2	6.0
		Pyrexia	n/a	90	100.0	1	1.1	0.2	6.0
	Hepatobiliary disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Cholangitis	n/a	90	100.0	1	1.1	0.2	6.0
		Hepatic function abnormal	n/a	90	100.0	1	1.1	0.2	6.0
	Immune system disorders	-Total	n/a	90	100.0	3	3.3	1.1	9.3

		Cytokine release syndrome	n/a	90	100.0	3	3.3	1.1	9.3
	Infections and infestations	-Total	n/a	90	100.0	15	16.7	10.4	25.7
		Anorectal infection	n/a	90	100.0	1	1.1	0.2	6.0
		COVID-19	n/a	90	100.0	2	2.2	0.6	7.7
		Cellulitis	n/a	90	100.0	1	1.1	0.2	6.0
		Enterocolitis bacterial	n/a	90	100.0	1	1.1	0.2	6.0
		Epstein-Barr viraemia	n/a	90	100.0	1	1.1	0.2	6.0
		Infection	n/a	90	100.0	1	1.1	0.2	6.0
		Klebsiella infection	n/a	90	100.0	1	1.1	0.2	6.0
		Pneumonia	n/a	90	100.0	3	3.3	1.1	9.3
		Sepsis	n/a	90	100.0	1	1.1	0.2	6.0
		Septic shock	n/a	90	100.0	2	2.2	0.6	7.7
		Staphylococcal bacteraemia	n/a	90	100.0	1	1.1	0.2	6.0
		Upper respiratory tract infection	n/a	90	100.0	2	2.2	0.6	7.7
		Urinary tract infection	n/a	90	100.0	1	1.1	0.2	6.0
	Injury, poisoning and procedural complications	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Hip fracture	n/a	90	100.0	1	1.1	0.2	6.0
		Subdural haematoma	n/a	90	100.0	1	1.1	0.2	6.0
	Investigations	-Total	n/a	90	100.0	15	16.7	10.4	25.7
		Alanine aminotransferase increased	n/a	90	100.0	5	5.6	2.4	12.4
		Aspartate aminotransferase increased	n/a	90	100.0	3	3.3	1.1	9.3
		Blood creatinine increased	n/a	90	100.0	1	1.1	0.2	6.0
		Blood fibrinogen decreased	n/a	90	100.0	1	1.1	0.2	6.0
		Blood phosphorus decreased	n/a	90	100.0	1	1.1	0.2	6.0
		C-reactive protein increased	n/a	90	100.0	1	1.1	0.2	6.0
		Gamma-glutamyltransferase increased	n/a	90	100.0	1	1.1	0.2	6.0
		Neutrophil count decreased	n/a	90	100.0	7	7.8	3.8	15.2

		Platelet count decreased	n/a	90	100.0	1	1.1	0.2	6.0
	Metabolism and nutrition disorders	-Total	n/a	90	100.0	25	27.8	19.6	37.8
		Hypercalcaemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hyperglycaemia	n/a	90	100.0	7	7.8	3.8	15.2
		Hypoglycaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypokalaemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hyponatraemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypophosphataemia	n/a	90	100.0	15	16.7	10.4	25.7
		Hypovolaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Malnutrition	n/a	90	100.0	1	1.1	0.2	6.0
		Tumour lysis syndrome	n/a	90	100.0	1	1.1	0.2	6.0
	Musculoskeletal and connective tissue disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Back pain	n/a	90	100.0	1	1.1	0.2	6.0
		Osteoarthritis	n/a	90	100.0	1	1.1	0.2	6.0
		Spinal stenosis	n/a	90	100.0	1	1.1	0.2	6.0
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	-Total	n/a	90	100.0	3	3.3	1.1	9.3
		Squamous cell carcinoma	n/a	90	100.0	1	1.1	0.2	6.0
		Tumour flare	n/a	90	100.0	2	2.2	0.6	7.7
	Nervous system disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Headache	n/a	90	100.0	1	1.1	0.2	6.0
		Presyncope	n/a	90	100.0	1	1.1	0.2	6.0
	Renal and urinary disorders	-Total	n/a	90	100.0	4	4.4	1.7	10.9
		Acute kidney injury	n/a	90	100.0	4	4.4	1.7	10.9
	Respiratory, thoracic and mediastinal disorders	-Total	n/a	90	100.0	4	4.4	1.7	10.9
		Dyspnoea	n/a	90	100.0	1	1.1	0.2	6.0
		Pleural effusion	n/a	90	100.0	1	1.1	0.2	6.0
		Pneumonitis	n/a	90	100.0	1	1.1	0.2	6.0

		Pulmonary oedema	n/a	90	100.0	1	1.1	0.2	6.0
	Skin and subcutaneous tissue disorders	-Total	n/a	90	100.0	4	4.4	1.7	10.9
		Rash	n/a	90	100.0	1	1.1	0.2	6.0
		Rash erythematous	n/a	90	100.0	2	2.2	0.6	7.7
		Rash papular	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.

All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_soc_JAN22_SE_B11E_MNP_AEGR345.xls

04MAR2022 9:03

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AEs Grade 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	44	48.9	38.8	59.0

95% CI based on Wilson Scores.
All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_MNP_AEGR3.xls
04MAR2022 8:55

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients

ENDPOINT: AEs Grade 3

MODEL: --

STUDY: GO29781

Dichotomous analysis (safety)

				B11 Exp 3L FL (RP2D) (N=90)					
Name	SOC	PT	Level	Patients		Patients with Event			
				n	%	n	%	95% CI (LL)	95% CI (UL)
All	Blood and lymphatic system disorders	-Total	n/a	90	100.0	13	14.4	8.6	23.2
		Anaemia	n/a	90	100.0	7	7.8	3.8	15.2
		Leukopenia	n/a	90	100.0	1	1.1	0.2	6.0
		Lymphopenia	n/a	90	100.0	3	3.3	1.1	9.3
		Neutropenia	n/a	90	100.0	7	7.8	3.8	15.2
	Endocrine disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Endocrine disorder	n/a	90	100.0	1	1.1	0.2	6.0
	Eye disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Cataract	n/a	90	100.0	1	1.1	0.2	6.0
	Gastrointestinal disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Abdominal pain	n/a	90	100.0	1	1.1	0.2	6.0
		Ascites	n/a	90	100.0	1	1.1	0.2	6.0
	General disorders and administration site conditions	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Chills	n/a	90	100.0	1	1.1	0.2	6.0
		Pyrexia	n/a	90	100.0	1	1.1	0.2	6.0
	Hepatobiliary disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Cholangitis	n/a	90	100.0	1	1.1	0.2	6.0
		Hepatic function abnormal	n/a	90	100.0	1	1.1	0.2	6.0
	Immune system disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Cytokine release syndrome	n/a	90	100.0	1	1.1	0.2	6.0
	Infections and infestations	-Total	n/a	90	100.0	12	13.3	7.8	21.9

		Hypokalaemia	n/a	90	100.0	2	2.2	0.6	7.7
		Hyponatraemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypophosphataemia	n/a	90	100.0	15	16.7	10.4	25.7
		Hypovolaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Malnutrition	n/a	90	100.0	1	1.1	0.2	6.0
	Musculoskeletal and connective tissue disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Back pain	n/a	90	100.0	1	1.1	0.2	6.0
		Osteoarthritis	n/a	90	100.0	1	1.1	0.2	6.0
		Spinal stenosis	n/a	90	100.0	1	1.1	0.2	6.0
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	-Total	n/a	90	100.0	3	3.3	1.1	9.3
		Squamous cell carcinoma	n/a	90	100.0	1	1.1	0.2	6.0
		Tumour flare	n/a	90	100.0	2	2.2	0.6	7.7
	Nervous system disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Headache	n/a	90	100.0	1	1.1	0.2	6.0
		Presyncope	n/a	90	100.0	1	1.1	0.2	6.0
	Renal and urinary disorders	-Total	n/a	90	100.0	3	3.3	1.1	9.3
		Acute kidney injury	n/a	90	100.0	3	3.3	1.1	9.3
	Respiratory, thoracic and mediastinal disorders	-Total	n/a	90	100.0	4	4.4	1.7	10.9
		Dyspnoea	n/a	90	100.0	1	1.1	0.2	6.0
		Pleural effusion	n/a	90	100.0	1	1.1	0.2	6.0
		Pneumonitis	n/a	90	100.0	1	1.1	0.2	6.0
		Pulmonary oedema	n/a	90	100.0	1	1.1	0.2	6.0
	Skin and subcutaneous tissue disorders	-Total	n/a	90	100.0	4	4.4	1.7	10.9
		Rash	n/a	90	100.0	1	1.1	0.2	6.0
		Rash erythematous	n/a	90	100.0	2	2.2	0.6	7.7
		Rash papular	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.

All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_soc_JAN22_SE_B11E_MNP_AEGR3.xls

04MAR2022 9:01

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AEs Grade 4
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	17	18.9	12.1	28.2

95% CI based on Wilson Scores.
All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_MNP_AEGR4.xls
04MAR2022 8:56

Dichotomous analysis (safety)

[illegible]

		Hypercalcaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Tumour lysis syndrome	n/a	90	100.0	1	1.1	0.2	6.0
	Renal and urinary disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Acute kidney injury	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.

All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFJ_Jan2022/prod/output/saf_raw_soc_JAN22_SE_B11E_MNP_AEGR4.xls

04MAR2022 9:02

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AEs Grade 5 (AEs leading to death)
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	2	2.2	0.6	7.7

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AEGR5.xls
04MAR2022 8:52

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AEs Grade 5 (AEs leading to death)
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_MNP_AEGR5.xls
10MAR2022 14:23

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AEs Grade 5 (AEs leading to death)
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

				B11 Exp 3L FL (RP2D) (N=90)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	General disorders and administration site conditions	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Death	n/a	90	100.0	1	1.1	0.2	6.0
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Malignant neoplasm progression	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_soc_JAN22_SE_B11E_AEGR5.xls
04MAR2022 8:56

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AEs Grade 5 (AEs leading to death)
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

				B11 Exp 3L FL (RP2D) (N=90)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	General disorders and administration site conditions	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Death	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_soc_JAN22_SE_B11E_MNP_AEGR5.xls
04MAR2022 9:03

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: Any SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	42	46.7	36.7	56.9

95% CI based on Wilson Scores.
All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_MNP_AESAE.xls
04MAR2022 8:58

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients

ENDPOINT: Any SAEs

MODEL: --

STUDY: GO29781

Dichotomous analysis (safety)

				B11 Exp 3L FL (RP2D) (N=90)					
Name	SOC	PT	Level	Patients		Patients with Event			
				n	%	n	%	95% CI (LL)	95% CI (UL)
All	Blood and lymphatic system disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Neutropenia	n/a	90	100.0	1	1.1	0.2	6.0
	Cardiac disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Bradycardia	n/a	90	100.0	1	1.1	0.2	6.0
	Gastrointestinal disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Abdominal pain	n/a	90	100.0	1	1.1	0.2	6.0
		Ascites	n/a	90	100.0	1	1.1	0.2	6.0
	General disorders and administration site conditions	-Total	n/a	90	100.0	3	3.3	1.1	9.3
		Death	n/a	90	100.0	1	1.1	0.2	6.0
		Pyrexia	n/a	90	100.0	2	2.2	0.6	7.7
	Hepatobiliary disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Cholangitis	n/a	90	100.0	1	1.1	0.2	6.0
		Cholecystitis acute	n/a	90	100.0	1	1.1	0.2	6.0
	Immune system disorders	-Total	n/a	90	100.0	21	23.3	15.8	33.1
		Cytokine release syndrome	n/a	90	100.0	21	23.3	15.8	33.1
	Infections and infestations	-Total	n/a	90	100.0	18	20.0	13.0	29.4
		Anorectal infection	n/a	90	100.0	1	1.1	0.2	6.0
		COVID-19	n/a	90	100.0	2	2.2	0.6	7.7
		Cellulitis	n/a	90	100.0	1	1.1	0.2	6.0
		Enterocolitis bacterial	n/a	90	100.0	1	1.1	0.2	6.0
		Epstein-Barr viraemia	n/a	90	100.0	2	2.2	0.6	7.7

		Herpes zoster	n/a	90	100.0	1	1.1	0.2	6.0
		Klebsiella infection	n/a	90	100.0	1	1.1	0.2	6.0
		Pneumonia	n/a	90	100.0	2	2.2	0.6	7.7
		Pyelonephritis acute	n/a	90	100.0	1	1.1	0.2	6.0
		Sepsis	n/a	90	100.0	1	1.1	0.2	6.0
		Septic shock	n/a	90	100.0	2	2.2	0.6	7.7
		Staphylococcal bacteraemia	n/a	90	100.0	1	1.1	0.2	6.0
		Upper respiratory tract infection	n/a	90	100.0	1	1.1	0.2	6.0
		Urinary tract infection	n/a	90	100.0	3	3.3	1.1	9.3
	Injury, poisoning and procedural complications	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Hip fracture	n/a	90	100.0	1	1.1	0.2	6.0
		Subdural haematoma	n/a	90	100.0	1	1.1	0.2	6.0
	Investigations	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Alanine aminotransferase increased	n/a	90	100.0	1	1.1	0.2	6.0
		Aspartate aminotransferase increased	n/a	90	100.0	1	1.1	0.2	6.0
	Metabolism and nutrition disorders	-Total	n/a	90	100.0	5	5.6	2.4	12.4
		Hypercalcaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypervolaemia	n/a	90	100.0	1	1.1	0.2	6.0
		Hypophosphataemia	n/a	90	100.0	1	1.1	0.2	6.0
		Malnutrition	n/a	90	100.0	1	1.1	0.2	6.0
		Tumour lysis syndrome	n/a	90	100.0	1	1.1	0.2	6.0
	Musculoskeletal and connective tissue disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Back pain	n/a	90	100.0	1	1.1	0.2	6.0
		Osteoarthritis	n/a	90	100.0	1	1.1	0.2	6.0
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Tumour flare	n/a	90	100.0	2	2.2	0.6	7.7
	Psychiatric disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7

		Confusional state	n/a	90	100.0	1	1.1	0.2	6.0
		Fear	n/a	90	100.0	1	1.1	0.2	6.0
	Renal and urinary disorders	-Total	n/a	90	100.0	3	3.3	1.1	9.3
		Acute kidney injury	n/a	90	100.0	3	3.3	1.1	9.3
	Respiratory, thoracic and mediastinal disorders	-Total	n/a	90	100.0	4	4.4	1.7	10.9
		Dyspnoea	n/a	90	100.0	1	1.1	0.2	6.0
		Laryngeal oedema	n/a	90	100.0	1	1.1	0.2	6.0
		Pleural effusion	n/a	90	100.0	1	1.1	0.2	6.0
		Pneumonitis	n/a	90	100.0	1	1.1	0.2	6.0
	Skin and subcutaneous tissue disorders	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Rash erythematous	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.

All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".

Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas

Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_soc_JAN22_SE_B11E_MNP_AESAE.xls

04MAR2022 9:05

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AEs leading to treatment discontinuation
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	4	4.4	1.7	10.9

95% CI based on Wilson Scores.
All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_MNP_AEDISC.xls
04MAR2022 8:58

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AEs leading to treatment discontinuation
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

				B11 Exp 3L FL (RP2D) (N=90)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	Immune system disorders	-Total	n/a	90	100.0	2	2.2	0.6	7.7
		Cytokine release syndrome	n/a	90	100.0	2	2.2	0.6	7.7
	Infections and infestations	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Epstein-Barr viraemia	n/a	90	100.0	1	1.1	0.2	6.0
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	-Total	n/a	90	100.0	1	1.1	0.2	6.0
		Hodgkin's disease	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_soc_JAN22_SE_B11E_MNP_AEDISC.xls
04MAR2022 9:05

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: GO29781
Outcome of Adverse Events

		B11 Exp 3L FL (RP2D) (N=90)														
		Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING	
Category of Adverse Events		n	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any AEs	All	1187	968	81.6	3	0.3	167	14.1	1	<0.1	42	3.5	6	0.5	0	0.0
	Grade 1	713	580	81.3	1	0.1	103	14.4	0	0.0	27	3.8	2	0.3	0	0.0
	Grade 2	301	233	77.4	0	0.0	51	16.9	0	0.0	14	4.7	3	1.0	0	0.0
	Grade 3	140	127	90.7	1	0.7	11	7.9	0	0.0	1	0.7	0	0.0	0	0.0
	Grade 4	32	28	87.5	1	3.1	2	6.3	0	0.0	0	0.0	1	3.1	0	0.0
	Grade 5	1	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0
	Grade >= 3	173	155	89.6	2	1.2	13	7.5	1	0.6	1	0.6	1	0.6	0	0.0
	Missing	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Any SAEs	All	90	83	92.2	2	2.2	3	3.3	1	1.1	1	1.1	0	0.0	0	0.0
AEs leading to treatment discontinuation	All	4	3	75.0	0	0.0	1	25.0	0	0.0	0	0.0	0	0.0	0	0.0

All analyses were performed excluding disease related/specific events, i.e. not considering any AE with PT "malignant neoplasm progression".
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_resolved.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_resolved_JAN22_SE_B11E_MNP.xls
04MAR2022 8:56

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	40	44.4	34.6	54.7

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRS.xls
04MAR2022 8:37

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - Grade 1
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	23	25.6	17.7	35.4

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRS1.xls
10MAY2022 10:06

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - Grade 2
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	15	16.7	10.4	25.7

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRS2.xls
10MAY2022 10:07

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - Grade >= 2
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	17	18.9	12.1	28.2

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRS2345.xls
12APR2022 8:41

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - Grade 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRS3.xls
10MAY2022 10:08

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	2	2.2	0.6	7.7

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRS345.xls
04MAR2022 8:38

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - Grade 4
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRS4.xls
10MAY2022 10:08

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by Lee grade
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	41	45.6	35.7	55.8

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRSL.xls
04MAR2022 8:39

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by Lee grade - Grade >= 2
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	18	20.0	13.0	29.4

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRSL2345.xls
12APR2022 8:44

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by Lee grade - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	3	3.3	1.1	9.3

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRSL345.xls
04MAR2022 8:40

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by Lee grade - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	21	23.3	15.8	33.1

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRSLSAE.xls
04MAR2022 8:41

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	21	23.3	15.8	33.1

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ACRSSAE.xls
04MAR2022 8:39

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Neurologic AEs and DI-CCNAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	59	65.6	55.3	74.6

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ANAE.xls
04MAR2022 8:41

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Neurologic AEs and DI-CCNAEs - Grade >= 2
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	16	17.8	11.2	26.9

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ANAE2345.xls
12APR2022 8:47

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Neurologic AEs and DI-CCNAEs - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	3	3.3	1.1	9.3

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ANAE345.xls
04MAR2022 8:42

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Neurologic AEs and DI-CCNAEs - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	3	3.3	1.1	9.3

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ANAESAE.xls
04MAR2022 8:42

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Hematologic AEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	34	37.8	28.5	48.1

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AHEMA.xls
04MAR2022 8:43

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Hematologic AEs - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	30	33.3	24.5	43.6

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AHEMA345.xls
04MAR2022 8:44

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Hematologic AEs - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AHEMASAE.xls
04MAR2022 8:45

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Hemophagocytic lymphohistiocytosis
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	0	0.0	0.0	4.1

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AHPCL.xls
04MAR2022 8:45

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Hemophagocytic lymphohistiocytosis - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	0	0.0	0.0	4.1

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AHPCL345.xls
04MAR2022 8:46

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Hemophagocytic lymphohistiocytosis - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	0	0.0	0.0	4.1

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AHPCLSAE.xls
04MAR2022 8:46

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Tumor lysis syndrome
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ATLS.xls
04MAR2022 8:47

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Tumor lysis syndrome - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ATLS345.xls
04MAR2022 8:47

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Tumor lysis syndrome - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ATLSSAE.xls
04MAR2022 8:48

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Tumor flare
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	3	3.3	1.1	9.3

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ATF.xls
04MAR2022 8:48

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Tumor flare - Grade >= 2
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	3	3.3	1.1	9.3

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ATF2345.xls
12APR2022 8:57

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Tumor flare - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	2	2.2	0.6	7.7

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ATF345.xls
04MAR2022 8:49

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Tumor flare - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	2	2.2	0.6	7.7

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_ATFSAE.xls
04MAR2022 8:50

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Hepatic AEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	12	13.3	7.8	21.9

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AHEP.xls
04MAR2022 8:50

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Hepatic AEs - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	6	6.7	3.1	13.8

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AHEP345.xls
04MAR2022 8:51

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Hepatic AEs - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AHEPSAE.xls
04MAR2022 8:51

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Infections
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	46	51.1	41.0	61.2

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AINF.xls
04MAR2022 8:52

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Infections - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	15	16.7	10.4	25.7

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AINF345.xls
04MAR2022 8:52

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Infections - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	18	20.0	13.0	29.4

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_AINFSAE.xls
04MAR2022 8:53

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Pneumonitis or interstitial lung disease
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_APILD.xls
04MAR2022 8:54

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Pneumonitis or interstitial lung disease - Grade >= 3
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_APILD345.xls
04MAR2022 8:54

POPULATION: Cohort B11 Expansion FL, Safety-Evaluable Patients
ENDPOINT: AESI: Pneumonitis or interstitial lung disease - SAEs
MODEL: --
STUDY: GO29781
Dichotomous analysis (safety)

		B11 Exp 3L FL (RP2D) (N=90)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	90	100.0	1	1.1	0.2	6.0

95% CI based on Wilson Scores.
Clinical cut-off: 03JAN2022

Program: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7030816/CDPT7828/GO29781/data_analysis/ACE_BLA_90D_SFU_Jan2022/prod/output/saf_raw_JAN22_SE_B11E_APILDSAE.xls
04MAR2022 8:55